<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="3b1ce049-1571-4d2d-add5-a046496204d6"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use JAKAFI safely and effectively. See full prescribing information for JAKAFI.
			<br/>
         <br/>JAKAFI<sup>®</sup> (ruxolitinib) tablets, for oral use
			<br/>Initial U.S. Approval: 2011
		</content>
   </title>
   <effectiveTime value="20250624"/>
   <setId root="f1c82580-87ae-11e0-bc84-0002a5d5c51b"/>
   <versionNumber value="39"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="556967347" root="1.3.6.1.4.1.519.1"/>
            <name>Incyte Corporation</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="4943517e-6c16-4c0d-aa91-07259d3c4329"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250624"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50881-005" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>JAKAFI</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>ruxolitinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5.0"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="82S8X8XX8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>RUXOLITINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="82S8X8XX8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RUXOLITINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="66O7AQV0RT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (70000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="60"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50881-005-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20111116"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA202192" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20111116"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>White to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">INCY;5</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50881-010" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>JAKAFI</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>ruxolitinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10.0"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="82S8X8XX8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>RUXOLITINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="82S8X8XX8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RUXOLITINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="66O7AQV0RT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (70000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="28"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50881-010-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20111116"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="60"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50881-010-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20111116"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA202192" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20111116"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>White to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">INCY;10</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50881-015" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>JAKAFI</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>ruxolitinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="15.0"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="82S8X8XX8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>RUXOLITINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="82S8X8XX8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RUXOLITINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="66O7AQV0RT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (70000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="60"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50881-015-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20111116"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA202192" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20111116"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>White to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">INCY;15</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="15" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50881-020" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>JAKAFI</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>ruxolitinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="20.0"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="82S8X8XX8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>RUXOLITINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="82S8X8XX8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RUXOLITINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="66O7AQV0RT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (70000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="60"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50881-020-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20111116"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA202192" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20111116"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>White to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">INCY;20</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="16" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50881-025" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>JAKAFI</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>ruxolitinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="25.0"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="82S8X8XX8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>RUXOLITINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="82S8X8XX8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RUXOLITINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="66O7AQV0RT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (70000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="60"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50881-025-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20111116"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA202192" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20111116"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>White to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">INCY;25</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_f6b6658a-ad7d-47d5-8b22-dfcbe2a7744c">
               <id root="5c0cca38-2dbb-4301-b3cf-aca29ac07133"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title/>
               <text>
                  <table>
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">kjhkj</td>
                           <td>bnvv </td>
                        </tr>
                        <tr>
                           <td> </td>
                           <td> </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250624"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%">
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td>Dosage and Administration, Monitoring to Assess Safety (<linkHtml href="#LINK_3b17b45d-c118-4187-81f6-cff746af2918">2.1</linkHtml>) </td>
                                 <td align="right">01/2023</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions, Risk of Infection (<linkHtml href="#LINK_4179c908-b0a4-444b-9c4c-a34b4adb23c6">5.2</linkHtml>)</td>
                                 <td align="right">01/2023</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_fa0ae43a-573e-488d-8660-f22ccda1fd88">
               <id root="f044d0a4-c10e-4169-82ea-db0eeb4dfd95"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1. INDICATIONS AND USAGE</title>
               <text/>
               <effectiveTime value="20250624"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Jakafi is a kinase inhibitor indicated for treatment of:</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adults. (<linkHtml href="#LINK_59b674e9-2ac3-4e77-b7df-161903a13155">1.1</linkHtml>)</item>
                           <item>polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea. (<linkHtml href="#LINK_4fa2a01f-c95a-4218-9c6f-aebaaee6e6d6">1.2</linkHtml>)</item>
                           <item>steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older (<linkHtml href="#LINK_66b2936e-8fc2-450f-8238-bd302d589e2a">1.3</linkHtml>)</item>
                           <item>chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. (<linkHtml href="#LINK_2876899a-cc40-4448-b9aa-37bb07beb1d1">1.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_59b674e9-2ac3-4e77-b7df-161903a13155">
                     <id root="5dcc8d38-c937-43aa-a25b-504abc105bab"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 	Myelofibrosis</title>
                     <text>
                        <paragraph>Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4fa2a01f-c95a-4218-9c6f-aebaaee6e6d6">
                     <id root="f30ba1d2-c920-44b9-aca0-174b0af6ff9b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Polycythemia Vera</title>
                     <text>
                        <paragraph>Jakafi is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_66b2936e-8fc2-450f-8238-bd302d589e2a">
                     <id root="8d932269-dc75-4521-8677-86751ba25dbc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Acute Graft-Versus-Host Disease</title>
                     <text>
                        <paragraph>Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2876899a-cc40-4448-b9aa-37bb07beb1d1">
                     <id root="91b3284b-fd65-4b13-8d0c-06574f0d270e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.4 Chronic
Graft-Versus-Host Disease</title>
                     <text>
                        <paragraph>Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_2757da7a-be91-4381-bd94-c7ea4a976fd2">
               <id root="4280115b-2118-4125-b26b-2d2a1fa42460"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2.  DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20250624"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Doses should be individualized based on safety and efficacy. Starting doses per indication are noted below.</paragraph>
                        <paragraph>Myelofibrosis (<linkHtml href="#LINK_0ef1fe96-9d7a-412c-b91c-f48627ed1c3b">2.2</linkHtml>)</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>The starting dose of Jakafi is based on patient’s baseline platelet count:<br/>
										  •  Greater than 200 x 10<sup>9</sup>/L: 20 mg given orally twice daily<br/>
										  •  100 x 10<sup>9</sup>/L to 200  x 10<sup>9</sup>/L: 15 mg given orally twice daily<br/>
										  •  50 x 10<sup>9</sup>/L to less than 100 x 10<sup>9</sup>/L: 5 mg given orally twice daily
									</item>
                           <item>Monitor complete blood counts every 2 to 4 weeks until doses are stabilized, and then as clinically indicated. Modify or interrupt dosing for thrombocytopenia.</item>
                        </list>
                        <paragraph>Polycythemia Vera (<linkHtml href="#LINK_29abdabb-4f07-4eb5-845b-97ba8b940ac9">2.3</linkHtml>)</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>The starting dose of Jakafi is 10 mg given orally twice daily.</item>
                        </list>
                        <paragraph>Acute Graft-Versus-Host Disease (<linkHtml href="#LINK_73306a47-692c-4d42-a8e9-a97fae787195">2.4</linkHtml>)</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <paragraph>The starting dose of Jakafi is 5 mg given orally twice daily.</paragraph>
                           </item>
                        </list>
                        <paragraph>Chronic Graft-Versus-Host Disease (<linkHtml href="#LINK_f893c970-6c92-4300-90f7-cf44ab70cb9d">2.5</linkHtml>)</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>The starting dose of Jakafi is 10 mg given orally twice daily.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_3b17b45d-c118-4187-81f6-cff746af2918">
                     <id root="6fbe10ec-b5bd-4672-830b-5cae326257d3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">2.1	Monitoring to Assess Safety</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="xmChange">Prior to Jakafi treatment:</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="xmChange">Perform a complete blood count <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_b4d13c83-97c5-4860-a1c6-04b5e89c93b1">5.1</linkHtml>)]</content>.</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Inquire about past infections, including tuberculosis, herpes simplex, herpes zoster, and hepatitis B <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_4179c908-b0a4-444b-9c4c-a34b4adb23c6">5.2</linkHtml>)]</content>.</content>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="italics">During treatment with Jakafi:</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="xmChange">Perform a complete blood count every 2 to 4 weeks until doses are stabilized, and then as clinically indicated <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_b4d13c83-97c5-4860-a1c6-04b5e89c93b1">5.1</linkHtml>)]</content>.</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Assess lipid parameters approximately 8-12 weeks following initiation of Jakafi therapy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_448a0b1c-1ed2-414b-bd9c-aecb282f3605">5.5</linkHtml>)]</content>.</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0ef1fe96-9d7a-412c-b91c-f48627ed1c3b">
                     <id root="a02517c6-5864-4479-a72c-b50c981454fe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Dosage for Myelofibrosis</title>
                     <text>
                        <paragraph>The recommended starting dose of Jakafi is based on platelet count (Table 1). Doses may be titrated based on safety and efficacy.</paragraph>
                        <table>
                           <caption>Table 1: Jakafi Starting Doses for Myelofibrosis</caption>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Platelet Count</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Starting Dose</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Greater than 200 x 10<sup>9</sup>/L</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> 20 mg orally twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> 100 x 10<sup>9</sup>/L to 200 x 10<sup>9</sup>/L</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> 15 mg orally twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> 50 x 10<sup>9</sup>/L to less than 100 x 10<sup>9</sup>/L      </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> 5 mg orally twice daily      </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250624"/>
                     <component>
                        <section ID="LINK_ff9d8a83-361f-40fe-942c-2e092156685d">
                           <id root="dcdcd9e9-f992-428c-a452-cee579e8c74d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold"> 	Dose Modification Guidelines for Hematologic Toxicity for Patients with Myelofibrosis Starting Treatment with a Platelet Count of 100 x 10<sup>9</sup>/L or Greater</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Treatment Interruption and Restarting Dosing</content>
                              </paragraph>
                              <paragraph>Interrupt treatment for platelet counts less than 50 x 10<sup>9</sup>/L or absolute neutrophil count (ANC) less than 0.5 x 10<sup>9</sup>/L.</paragraph>
                              <paragraph>After recovery of platelet counts above 50 x 10<sup>9</sup>/L and ANC above 0.75 x 10<sup>9</sup>/L, dosing may be restarted. Table 2 illustrates the maximum allowable dose that may be used in restarting Jakafi after a previous interruption.</paragraph>
                              <table width="60%">
                                 <caption>Table 2: Myelofibrosis: Maximum Restarting Doses for Jakafi after Safety Interruption for Thrombocytopenia for Patients Starting Treatment with a Platelet Count of 100 x 10<sup>9</sup>/L or Greater</caption>
                                 <col width="1px"/>
                                 <col width="1px"/>
                                 <tbody>
                                    <tr>
                                       <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule"> <content styleCode="bold">Current Platelet Count</content>
                                       </td>
                                       <td align="center" styleCode=" Toprule Rrule"> <content styleCode="bold">Maximum Dose When
														<br/>Restarting Jakafi Treatment<footnote ID="FOOT_8351">Maximum doses are displayed. When restarting, begin with a dose at least 5 mg twice daily below the dose at interruption.</footnote> </content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode=" Toprule Lrule Rrule"> Greater than or equal to 125 x 10<sup>9</sup>/L</td>
                                       <td styleCode=" Toprule Rrule">20 mg twice daily</td>
                                    </tr>
                                    <tr>
                                       <td styleCode=" Toprule Lrule Rrule"> 100 to less than 125 x 10<sup>9</sup>/L</td>
                                       <td styleCode=" Toprule Rrule">15 mg twice daily</td>
                                    </tr>
                                    <tr>
                                       <td styleCode=" Toprule Lrule Rrule"> 75 to less than 100 x 10<sup>9</sup>/L</td>
                                       <td styleCode=" Toprule Rrule">10 mg twice daily for at least 2 weeks; if stable, may increase to 15 mg twice daily</td>
                                    </tr>
                                    <tr>
                                       <td styleCode=" Toprule Lrule Rrule"> 50 to less than 75 x 10<sup>9</sup>/L</td>
                                       <td styleCode=" Toprule Rrule">5 mg twice daily for at least 2 weeks; if stable, may increase to 10 mg twice daily</td>
                                    </tr>
                                    <tr>
                                       <td styleCode=" Botrule Toprule Lrule Rrule"> Less than 50 x 10<sup>9</sup>/L</td>
                                       <td styleCode=" Botrule Toprule Rrule">Continue hold</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Following treatment interruption for ANC below 0.5 x 10<sup>9</sup>/L, after ANC recovers to 0.75 x 10<sup>9</sup>/L or greater, restart dosing at the higher of 5 mg once daily or 5 mg twice daily below the largest dose in the week prior to the treatment interruption.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Dose Reductions</content>
                                 <br/>Dose reductions should be considered if the platelet counts decrease as outlined in Table 3 with the goal of avoiding dose interruptions for thrombocytopenia.</paragraph>
                              <table width="600px">
                                 <caption>Table 3: Myelofibrosis: Dosing Recommendations for Thrombocytopenia for Patients Starting Treatment with a Platelet Count of 100 x 10<sup>9</sup>/L or Greater</caption>
                                 <col/>
                                 <col/>
                                 <col/>
                                 <col/>
                                 <col/>
                                 <col/>
                                 <tbody>
                                    <tr>
                                       <td styleCode=" Botrule Toprule Lrule Rrule">  </td>
                                       <td align="center" colspan="5" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Dose at Time of Platelet Decline</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Platelet Count</content>
                                       </td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                          <content styleCode="bold"> 25 mg  
														<br/>twice<br/>daily</content>
                                       </td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule">  <content styleCode="bold">20 mg  
														<br/>twice<br/>daily</content>
                                       </td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">15 mg  
														<br/>twice<br/>daily</content>
                                       </td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">10 mg  
														<br/>twice<br/>daily</content>
                                       </td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">5 mg
 <br/>twice<br/>daily</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                          <content styleCode="bold">New<br/>Dose</content>
                                       </td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                          <content styleCode="bold">New<br/>Dose</content>
                                       </td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                          <content styleCode="bold">New<br/>Dose</content>
                                       </td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                          <content styleCode="bold">New<br/>Dose</content>
                                       </td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                          <content styleCode="bold">New<br/>Dose</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode=" Botrule Toprule Lrule Rrule">100 to less than <br/>125 x 10<sup>9</sup>/L</td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 20 mg
														<br/>twice<br/>daily
													</td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 15 mg
														<br/>twice<br/>daily
													</td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> No<br/> Change  </td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> No<br/> Change  </td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> No<br/> Change  </td>
                                    </tr>
                                    <tr>
                                       <td styleCode=" Botrule Toprule Lrule Rrule">75 to less than <br/>100 x 10<sup>9</sup>/L</td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 10 mg
														<br/>twice<br/>daily
													</td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 10 mg
														<br/>twice<br/>daily
													</td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 10 mg
														<br/>twice<br/>daily
													</td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> No<br/>Change</td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> No<br/>Change</td>
                                    </tr>
                                    <tr>
                                       <td styleCode=" Botrule Toprule Lrule Rrule">50 to less than <br/>75 x 10<sup>9</sup>/L</td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 5 mg
														<br/>twice<br/>daily
													</td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 5 mg
														<br/>twice<br/>daily
													</td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 5 mg
														<br/>twice<br/>daily
													</td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 5 mg
														<br/>twice<br/>daily
													</td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> No<br/>Change</td>
                                    </tr>
                                    <tr>
                                       <td styleCode=" Botrule Toprule Lrule Rrule">Less than 50 x 10<sup>9</sup>/L   </td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Hold</td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Hold</td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Hold</td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Hold</td>
                                       <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Hold</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250624"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_ae95a7d8-820d-4465-9c58-6923603206f9">
                           <id root="d73fdaef-7af4-45d2-aefe-04591f21997d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Dose Modification Based on Insufficient Response for Patients with Myelofibrosis Starting Treatment with a Platelet Count of 100 x 10<sup>9</sup>/L or Greater</content>
                           </title>
                           <text>
                              <paragraph>If the response is insufficient and platelet and neutrophil counts are adequate, doses may be increased in 5 mg twice daily increments to a maximum of 25 mg twice daily. Doses should not be increased during the first 4 weeks of therapy and not more frequently than every 2 weeks.</paragraph>
                              <paragraph>Consider dose increases in patients who meet all of the following conditions:</paragraph>
                              <list listType="ordered" styleCode="LittleAlpha">
                                 <item>Failure to achieve a reduction from pretreatment baseline in either palpable spleen length of 50% or a 35% reduction in spleen volume as measured by computed tomography (CT) or magnetic resonance imaging (MRI);</item>
                                 <item>Platelet count greater than 125 x 10<sup>9</sup>/L at 4 weeks and platelet count never below 100 x 10<sup>9</sup>/L;</item>
                                 <item>ANC Levels greater than 0.75 x 10<sup>9</sup>/L.</item>
                              </list>
                              <paragraph>Based on limited clinical data, long-term maintenance at a 5 mg twice daily dose has not shown responses and continued use at this dose should be limited to patients in whom the benefits outweigh the potential risks. Discontinue Jakafi if there is no spleen size reduction or symptom improvement after 6 months of therapy.</paragraph>
                           </text>
                           <effectiveTime value="20250624"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_59466bf0-99d6-4087-b8d3-18d57a4eee8e">
                           <id root="cf8f2017-b6bc-40e2-848e-16292b57920d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">	Dose Modifications for Hematologic Toxicity for Patients with Myelofibrosis  Starting Treatment with Platelet Counts of 50 x 10<sup>9</sup>/L to Less Than 100 x 10<sup>9</sup>/L</content>
                           </title>
                           <text>
                              <paragraph>This section applies only to patients with platelet counts of 50 x 10<sup>9</sup>/L to less than 100 x 10<sup>9</sup>/L prior to any treatment with Jakafi. See dose modifications in Section <linkHtml href="#www.splportal.comLINK_0ef1fe96-9d7a-412c-b91c-f48627ed1c3b">2.2</linkHtml> <content styleCode="italics">(Dose Modification Guidelines for Hematological Toxicity for Patients with Myelofibrosis Starting Treatment with a Platelet Count of 100 x 10<sup>9</sup>/L or Greater</content>
                                 <content styleCode="italics">) </content>for hematological toxicity in patients whose platelet counts were 100 x 10<sup>9</sup>/L or more prior to starting treatment with Jakafi.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Treatment Interruption and Restarting Dosing</content>
                              </paragraph>
                              <paragraph>Interrupt treatment for platelet counts less than 25 x 10<sup>9</sup>/L or ANC less than 0.5 x 10<sup>9</sup>/L.</paragraph>
                              <paragraph>After recovery of platelet counts above 35 x 10<sup>9</sup>/L and ANC above 0.75 x 10<sup>9</sup>/L, dosing may be restarted. Restart dosing at the higher of 5 mg once daily or 5 mg twice daily below the largest dose in the week prior to the decrease in platelet count below 25 x 10<sup>9</sup>/L or ANC below 0.5 x 10<sup>9</sup>/L that led to dose interruption.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Dose Reductions</content>
                              </paragraph>
                              <paragraph>Reduce the dose of Jakafi for platelet counts less than 35 x 10<sup>9</sup>/L as described in Table 4.</paragraph>
                              <table width="650px">
                                 <caption>Table 4: Myelofibrosis: Dosing Modifications for Thrombocytopenia for Patients with Starting Platelet Count of 50 x 10<sup>9</sup>/L to Less Than 100 x 10<sup>9</sup>/L</caption>
                                 <col width="1px"/>
                                 <col width="1px"/>
                                 <tbody>
                                    <tr>
                                       <td styleCode=" Botrule Lrule Rrule">
                                          <content styleCode="bold">Platelet Count</content>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Lrule Rrule"> <content styleCode="bold">  Dosing Recommendations</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode=" Botrule Lrule Rrule">Less than 25 x 10<sup>9</sup>/L</td>
                                       <td valign="top" styleCode=" Botrule Lrule Rrule">
                                          <list listType="unordered" styleCode="Disk">
                                             <item>Interrupt dosing.</item>
                                          </list>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode=" Botrule Lrule Rrule">
                                          <paragraph>25 x 10<sup>9</sup>/L to less than 35 x 10<sup>9</sup>/L<br/>
                                             <br/>AND the platelet count decline is  <br/>less than 20% during the prior four <br/>weeks</paragraph>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Lrule Rrule">
                                          <list listType="unordered" styleCode="Disk">
                                             <item>Decrease dose by 5 mg once daily.</item>
                                             <item>For patients on 5 mg once daily, maintain dose at 5 mg once daily.</item>
                                          </list>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Botrule Lrule Rrule">
                                          <paragraph>25 x 10<sup>9</sup>/L to less than 35 x 10<sup>9</sup>/L<br/>
                                             <br/>AND the platelet count decline is   <br/>20% or greater during the prior four weeks</paragraph>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Lrule Rrule">
                                          <list listType="unordered" styleCode="Disk">
                                             <item>Decrease dose by 5 mg twice daily.</item>
                                             <item>For patients on 5 mg twice daily, decrease the dose to 5 mg once daily.</item>
                                             <item>For patients on 5 mg once daily, maintain dose at 5 mg once daily.</item>
                                          </list>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250624"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_06591a44-710d-4cfb-9357-d06e569ff845">
                           <id root="c9d9d5ea-e9f8-4938-b891-b98176f93b13"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Dose Modifications Based on Insufficient Response for Patients with Myelofibrosis and Starting Platelet Count of 50 x 10<sup>9</sup>/L to Less Than 100 x 10<sup>9</sup>/L</content>
                           </title>
                           <text>
                              <paragraph>Do not increase doses during the first 4 weeks of therapy, and do not increase the dose more frequently than every 2 weeks.</paragraph>
                              <paragraph>If the response is insufficient as defined in Section <linkHtml href="#www.splportal.comLINK_0ef1fe96-9d7a-412c-b91c-f48627ed1c3b">2.2</linkHtml> <content styleCode="italics">(see Dose Modification Based on Insufficient Response with Myelofibrosis Starting Treatment with a platelet count of 100 x 10<sup>9</sup>/L or Greater)</content>, doses may be increased by increments of 5 mg daily to a maximum of 10 mg twice daily if:</paragraph>
                              <list listType="ordered" styleCode="LittleAlpha">
                                 <item>the platelet count has remained at least 40 x 10<sup>9</sup>/L, and</item>
                                 <item>the platelet count has not fallen by more than 20% in the prior 4 weeks, and</item>
                                 <item>the ANC is more than 1 x 10<sup>9</sup>/L, and</item>
                                 <item>the dose has not been reduced or interrupted for an adverse event or hematological toxicity in the prior 4 weeks.</item>
                              </list>
                              <paragraph>Continuation of treatment for more than 6 months should be limited to patients in whom the benefits outweigh the potential risks. Discontinue Jakafi if there is no spleen size reduction or symptom improvement after 6 months of therapy.</paragraph>
                           </text>
                           <effectiveTime value="20250624"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_5fe749fd-04c0-47a0-a490-e029c2fca478">
                           <id root="f52301b7-689a-4fc7-8374-f71f54ff9758"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Dose Modification for Bleeding</content>
                           </title>
                           <text>
                              <paragraph>Interrupt treatment for bleeding requiring intervention regardless of current platelet count. Once the bleeding event has resolved, consider resuming treatment at the prior dose if the underlying cause of bleeding has been controlled. If the bleeding event has resolved but the underlying cause persists, consider resuming treatment with Jakafi at a lower dose.</paragraph>
                           </text>
                           <effectiveTime value="20250624"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_29abdabb-4f07-4eb5-845b-97ba8b940ac9">
                     <id root="f4bb413e-dead-451a-b018-d195c91dff67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Recommended Dosage for Polycythemia Vera</title>
                     <text>
                        <paragraph>The recommended starting dose of Jakafi is 10 mg twice daily. Doses may be titrated based on safety and efficacy.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                     <component>
                        <section ID="LINK_80cbe678-a003-4f27-ad4e-9e75298fcaed">
                           <id root="09c37ee4-d5c2-4e0b-a617-8785672774dc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Dose Modification Guidelines for Patients with Polycythemia Vera</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Dose Reductions</content>
                              </paragraph>
                              <paragraph>Dose reductions should be considered for hemoglobin and platelet count decreases as described in Table 5.</paragraph>
                              <table>
                                 <caption>Table 5: Polycythemia Vera: Dose Reductions</caption>
                                 <col width="300px"/>
                                 <col width="350px"/>
                                 <tbody>
                                    <tr>
                                       <td styleCode=" Botrule Toprule Lrule Rrule">
                                          <content styleCode="bold">Hemoglobin and/or Platelet Count</content>
                                       </td>
                                       <td styleCode=" Botrule Toprule Lrule Rrule">
                                          <content styleCode="bold">Dosing Recommendations </content> </td>
                                    </tr>
                                    <tr>
                                       <td styleCode=" Botrule Toprule Lrule Rrule">Hemoglobin greater than or equal to 12 g/dL AND platelet count greater than or equal to 100 x 10<sup>9</sup>/L</td>
                                       <td styleCode=" Botrule Toprule Lrule Rrule">
                                          <list listType="unordered" styleCode="Disk">
                                             <item>No change required.</item>
                                          </list>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode=" Botrule Toprule Lrule Rrule">Hemoglobin 10 to less than 12 g/dL AND platelet count 75 to less than 100 x 10<sup>9</sup>/L</td>
                                       <td styleCode=" Botrule Toprule Lrule Rrule">
                                          <list listType="unordered" styleCode="Disk">
                                             <item>Dose reductions should be considered with the goal of avoiding dose interruptions for anemia and thrombocytopenia. </item>
                                          </list>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode=" Botrule Toprule Lrule Rrule">Hemoglobin 8 to less than 10 g/dL OR platelet count 50 to less than 75 x 10<sup>9</sup>/L</td>
                                       <td styleCode=" Botrule Toprule Lrule Rrule">
                                          <list listType="unordered" styleCode="Disk">
                                             <item>Reduce dose by 5 mg twice daily.</item>
                                             <item>For patients on 5 mg twice daily, decrease the dose to 5 mg once daily.</item>
                                          </list>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode=" Botrule Toprule Lrule Rrule">Hemoglobin less than 8 g/dL OR platelet count less than 50 x 10<sup>9</sup>/L</td>
                                       <td styleCode=" Botrule Toprule Lrule Rrule">
                                          <list listType="unordered" styleCode="Disk">
                                             <item>Interrupt dosing.</item>
                                          </list>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <content styleCode="bold">Treatment Interruption and Restarting Dosing</content>
                              </paragraph>
                              <paragraph>Interrupt treatment for hemoglobin less than 8 g/dL, platelet counts less than 50 x 10<sup>9</sup>/L or ANC less than 1.0 x 10<sup>9</sup>/L. </paragraph>
                              <paragraph>After recovery of the hematologic parameter(s) to acceptable levels, dosing may be restarted.</paragraph>
                              <paragraph>Table 6 illustrates the dose that may be used in restarting Jakafi after a previous interruption.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Table 6: Polycythemia Vera: Restarting Doses for Jakafi after Safety Interruption for Hematologic Parameter(s)</content>
                              </paragraph>
                              <paragraph>Use the <content styleCode="bold">
                                    <content styleCode="underline">most severe category</content>
                                 </content> of a patient’s hemoglobin, platelet count, or ANC abnormality to determine the corresponding maximum restarting dose.</paragraph>
                              <table>
                                 <col/>
                                 <col/>
                                 <tbody>
                                    <tr>
                                       <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                          <content styleCode="bold">Hemoglobin, Platelet Count, or ANC</content>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                          <content styleCode="bold">Maximum Restarting Dose</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode=" Botrule Lrule Rrule">Hemoglobin less than 8 g/dL OR <br/>
platelet count less than 50 x 10<sup>9</sup>/L OR <br/>
ANC less than 1 x 10<sup>9</sup>/L
													</td>
                                       <td valign="top" styleCode=" Botrule Lrule Rrule">Continue hold</td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Botrule Lrule Rrule">Hemoglobin 8 to less than 10 g/dL OR <br/>
platelet count 50 to less than 75 x 10<sup>9</sup>/L OR <br/>
ANC 1 to less than 1.5 x 10<sup>9</sup>/L
													</td>
                                       <td valign="top" styleCode=" Botrule Lrule Rrule">5 mg twice daily<footnote ID="FOOT_8352">Continue treatment for at least 2 weeks; if stable, may increase dose by 5 mg twice daily.</footnote>or no more than<br/>5 mg twice daily less than the dose <br/>which resulted in dose interruption</td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Botrule Lrule Rrule">Hemoglobin 10 to less than 12 g/dL OR <br/>
platelet count 75 to less than  100 x 10<sup>9</sup>/L OR <br/>
ANC 1.5 to less than 2  x 10<sup>9</sup>/L
													</td>
                                       <td valign="top" styleCode=" Botrule Lrule Rrule">10 mg twice daily<footnoteRef IDREF="FOOT_8352"/>or no more than<br/>5 mg twice daily less than the dose<br/>which resulted in dose interruption</td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Botrule Lrule Rrule">Hemoglobin greater than or equal to 12 g/dL OR <br/>
platelet count greater than or equal to 100 x 10<sup>9</sup>/L OR<br/>ANC greater than or equal to 2 x 10<sup>9</sup>/L
													</td>
                                       <td valign="top" styleCode=" Botrule Lrule Rrule">15 mg twice daily<footnoteRef IDREF="FOOT_8352"/>or no more than<br/>5 mg twice daily less than the dose<br/>which resulted in dose interruption       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Patients who had required dose interruption while receiving a dose of 5 mg twice daily, may restart at a dose of 5 mg twice daily or 5 mg once daily, but not higher, once hemoglobin is greater than or equal to 10 g/dL, platelet count is greater than or equal to 75 x 10<sup>9</sup>/L, and ANC is greater than or equal to 1.5 x 10<sup>9</sup>/L.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Dose Management after Restarting Treatment</content>
                              </paragraph>
                              <paragraph>After restarting Jakafi following treatment interruption, doses may be titrated, but the maximum total daily dose should not exceed 5 mg less than the dose that resulted in the dose interruption.  An exception to this is dose interruption following phlebotomy-associated anemia, in which case the maximal total daily dose allowed after restarting Jakafi would not be limited.</paragraph>
                           </text>
                           <effectiveTime value="20250624"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_d56ba4d5-21e0-4370-9776-6ea0b042e671">
                           <id root="2256f8fc-2cee-4c87-8590-c7c782e9bebd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Dose Modifications Based on Insufficient Response for Patients with Polycythemia Vera</content>
                           </title>
                           <text>
                              <paragraph>If the response is insufficient and platelet, hemoglobin, and neutrophil counts are adequate, doses may be increased in 5 mg twice daily increments to a maximum of 25 mg twice daily.  Doses should not be increased during the first 4 weeks of therapy and not more frequently than every two weeks.</paragraph>
                              <paragraph>Consider dose increases in patients who meet all of the following conditions: </paragraph>
                              <list listType="ordered" styleCode="Arabic">
                                 <item>Inadequate efficacy as demonstrated by one or more of the following:<list listType="ordered" styleCode="LittleAlpha">
                                       <item>Continued need for phlebotomy</item>
                                       <item>WBC greater than the upper limit of normal range</item>
                                       <item>Platelet count greater than the upper limit of normal range</item>
                                       <item>Palpable spleen that is reduced by less than 25% from Baseline</item>
                                    </list>
                                 </item>
                                 <item>Platelet count greater than or equal to 140 x 10<sup>9</sup>/L</item>
                                 <item>Hemoglobin greater than or equal to 12 g/dL</item>
                                 <item>ANC greater than or equal to 1.5 x 10<sup>9</sup>/L</item>
                              </list>
                           </text>
                           <effectiveTime value="20250624"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_73306a47-692c-4d42-a8e9-a97fae787195">
                     <id root="bb418395-5000-42c5-9791-e9d560c7021b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Recommended Dosage for Acute Graft-Versus-Host Disease</title>
                     <text>
                        <paragraph>The recommended starting dose of Jakafi is 5 mg given orally twice daily. Consider increasing the dose to 10 mg twice daily after at least 3 days of treatment if the ANC and platelet counts are not decreased by 50% or more relative to the first day of dosing with Jakafi.</paragraph>
                        <paragraph>Consider tapering Jakafi after 6 months of treatment in patients with response who have discontinued therapeutic doses of corticosteroids. Taper Jakafi by one dose level approximately every 8 weeks (10 mg twice daily to 5 mg twice daily to 5 mg once daily). If aGVHD signs or symptoms recur during or after the taper of Jakafi, consider retreatment.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Dose Modification Guidelines for Patients with Acute Graft-Versus-Host Disease</content>
                        </paragraph>
                        <paragraph>Monitor complete blood counts (CBC), including platelet count and ANC, and bilirubin prior to initiating therapy, every 2 to 4 weeks until doses are stabilized, and then as indicated clinically. </paragraph>
                        <paragraph> Modify the dose of Jakafi for adverse reactions as described in Table 7. For dose reductions, patients who are currently receiving Jakafi 10 mg twice daily may have their dose reduced to 5 mg twice daily; patients receiving 5 mg twice daily may have their dose reduced to 5 mg once daily. Patients who are unable to tolerate Jakafi at a dose of 5 mg once daily should have treatment interrupted until their clinical and/or laboratory parameters recover.</paragraph>
                        <table>
                           <caption>Table 7: Dose Modifications for Adverse Reactions in Patients with Acute GVHD</caption>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Laboratory Parameter</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Dosing Recommendations</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Clinically significant<br/>thrombocytopenia after supportive<br/>measures</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Reduce dose by 1 dose level.<br/>When platelets recover to previous values, dosing may<br/>return to prior dose level. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">ANC less than 1 x 10<sup>9</sup>/L<br/>considered related to Jakafi</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Hold Jakafi for up to 14 days; resume at 1 dose level<br/>lower upon recovery. </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Total Bilirubin elevation, no liver<br/>GVHD</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">3.0−5.0 x ULN:  Continue Jakafi at 1 dose level lower<br/>until recovery. <paragraph>&gt; 5.0−10.0 x ULN:  Hold Jakafi for up to 14 days until<br/>bilirubin ≤ 1.5 x ULN; resume at current dose upon<br/>recovery.</paragraph>
                                    <paragraph> Total bilirubin &gt; 10.0 x ULN: Hold Jakafi for up to<br/>14 days until bilirubin ≤ 1.5 x ULN; resume at 1 dose<br/>level lower upon recovery.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Total Bilirubin elevation, liver<br/>GVHD</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">&gt; 3.0 × ULN:  Continue Jakafi at 1 dose level lower<br/>until recovery.</td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f893c970-6c92-4300-90f7-cf44ab70cb9d">
                     <id root="7752bc9f-d485-4d21-96e4-4a6c845403a3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Recommended Dosage for Chronic Graft-Versus-Host Disease</title>
                     <text>
                        <paragraph>The recommended starting dose of Jakafi is 10 mg given orally twice daily. </paragraph>
                        <paragraph>Consider tapering Jakafi after 6 months of treatment in patients with response who have discontinued therapeutic doses of corticosteroids. Taper Jakafi by one dose level approximately every 8 weeks (10 mg twice daily to 5 mg twice daily to 5 mg once daily). If GVHD signs or symptoms recur during or after the taper of Jakafi, consider retreatment.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Dose Modification Guidelines for Patients with Chronic Graft-Versus-Host Disease</content>
                        </paragraph>
                        <paragraph>Monitor complete blood counts (CBC), including platelet count and ANC, and bilirubin prior to initiating therapy, every 2 to 4 weeks until doses are stabilized, and then as indicated clinically. </paragraph>
                        <paragraph> Modify the dose of Jakafi for adverse reactions as described in Table 8. For dose reductions, patients who are currently receiving Jakafi 10 mg twice daily may have their dose reduced to 5 mg twice daily; patients receiving 5 mg twice daily may have their dose reduced to 5 mg once daily. Patients who are unable to tolerate Jakafi at a dose of 5 mg once daily should have treatment interrupted until their clinical and/or laboratory parameters recover.</paragraph>
                        <table>
                           <caption>Table 8: Dose Modifications for Adverse Reactions in Patients with Chronic GVHD</caption>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Parameter</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Dosing Recommendations</content> </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Platelet count less than 20 × 10<sup>9</sup>/L </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Reduce Jakafi by 1 dose level. If resolved within 7 days, dosing may return to initial dose level. If not resolved within 7 days, then maintain at 1 dose level lower.</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Lrule Rrule">
                                    <paragraph>ANC less than 0.75 × 10<sup>9</sup>/L considered related to Jakafi</paragraph>
                                 </td>
                                 <td styleCode=" Rrule">
                                    <paragraph>Reduce Jakafi by 1 dose level; resume at initial dose level upon recovery.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Lrule">
                                    <paragraph>ANC less than 0.5 × 10<sup>9</sup>/L considered related to Jakafi</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Hold Jakafi for up to 14 days; resume at 1 dose level lower upon recovery. May resume initial dose level when ANC greater than 1.0 × 10<sup>9</sup>/L.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Lrule">
                                    <paragraph>Total Bilirubin: 3.0-5.0 × ULN</paragraph>
                                 </td>
                                 <td styleCode=" Lrule Rrule">
                                    <paragraph>Continue Jakafi at 1 dose level lower until recovery. If resolved within 14 days, then increase by one dose level. If not resolved within 14 days, then maintain the decreased dose level.<br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Lrule">
                                    <paragraph>Total Bilirubin: &gt; 5.0-10.0 × ULN</paragraph>
                                 </td>
                                 <td styleCode=" Lrule Rrule">
                                    <paragraph>Hold Jakafi for up to 14 days until resolved; resume at current dose upon recovery. If not resolved within 14 days, then resume at 1 dose level lower upon recovery.<br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Lrule">Total Bilirubin: &gt; 10.0 × ULN</td>
                                 <td styleCode=" Lrule Rrule">
                                    <paragraph>Hold Jakafi for up to 14 days until resolved; resume at 1 dose level lower upon recovery. If not resolved within 14 days, discontinue.<br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">Other Adverse Reactions: Grade 3</td>
                                 <td styleCode=" Toprule Rrule">Continue Jakafi at 1 dose level lower until recovery.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Lrule Rrule">Other Adverse Reactions: Grade 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule">Discontinue Jakafi.</td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_be19d915-2084-4e5a-905e-54d7e9de7464">
                     <id root="95036e45-4fa1-40d7-9f8d-eb88543addf6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Dose Modifications for Concomitant Use with Strong CYP3A4 Inhibitors or Fluconazole</title>
                     <text>
                        <paragraph>Modify the Jakafi dosage when coadministered with strong CYP3A4 inhibitors or doses of less than or equal to 200 mg of fluconazole <content styleCode="italics">[see Drug Interactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_af04531c-2dc2-45cb-bcd6-83d16e2c9b33">7</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>, according to Table 9. Avoid concomitant use of Jakafi with fluconazole doses of greater than 200 mg daily.</paragraph>
                        <table width="650px">
                           <caption>Table 9: Dose Modifications for Concomitant Use with Strong CYP3A4 Inhibitors or Fluconazole</caption>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">
                                       <content styleCode="bold">For patients coadministered strong CYP3A4 inhibitors or doses of less than or equal to 200 mg of fluconazole</content>
                                    </content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Recommended <content styleCode="bold">Jakafi </content>Dose Modification</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Lrule Rrule">
                                    <content styleCode="bold">Starting dose for patients with MF with a platelet count:   </content>
                                 </td>
                                 <td styleCode=" Botrule Lrule Rrule"> </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Lrule Rrule">
                                    <list listType="unordered" styleCode="Disk">
                                       <item>Greater than or equal to 100 x 10<sup>9</sup>/L</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode=" Botrule Lrule Rrule">10 mg twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Lrule Rrule">
                                    <list listType="unordered" styleCode="Disk">
                                       <item>50 x 10<sup>9</sup>/L to less than 100 x 10<sup>9</sup>/L</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode=" Botrule Lrule Rrule">5 mg once daily</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Lrule Rrule">
                                    <content styleCode="bold">Starting dose for patients with PV:</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Lrule Rrule">5 mg twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Lrule Rrule">
                                    <content styleCode="bold">If on stable dose for patients with MF or PV:</content>
                                 </td>
                                 <td styleCode=" Botrule Lrule Rrule"> </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Lrule Rrule">
                                    <list listType="unordered" styleCode="Disk">
                                       <item>Greater than or equal to 10 mg twice daily</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode=" Botrule Lrule Rrule">Decrease dose by 50% <br/>
												(round up to the closest available tablet strength)
											</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Lrule Rrule">
                                    <list listType="unordered" styleCode="Disk">
                                       <item>5 mg twice daily</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode=" Botrule Lrule Rrule">5 mg once daily</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Lrule Rrule">
                                    <list listType="unordered" styleCode="Disk">
                                       <item>5 mg once daily</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode=" Botrule Lrule Rrule">Avoid strong CYP3A4 inhibitor or fluconazole
												treatment or interrupt Jakafi treatment for the duration of strong CYP3A4 inhibitor or fluconazole use</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Lrule Rrule">
                                    <content styleCode="bold">
                                       <content styleCode="bold">Starting dose</content>
                                       <content styleCode="bold">for patients with aGVHD or cGVHD:</content>
                                    </content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Lrule Rrule">Fluconazole doses of less than or equal to 200 mg</td>
                                 <td align="center" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>5 mg once daily for patients with aGVHD;<br/>5 mg twice daily for patients with cGVHD </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Lrule Rrule">Other CYP3A4 inhibitors</td>
                                 <td align="center" styleCode=" Botrule Lrule Rrule">Monitor blood counts more frequently for toxicity and modify the Jakafi dosage for adverse reactions if they occur <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_73306a47-692c-4d42-a8e9-a97fae787195">2.4</linkHtml>
                                    </content>
                                    <content styleCode="italics">, <linkHtml href="#www.splportal.comLINK_f893c970-6c92-4300-90f7-cf44ab70cb9d">2.5</linkHtml>
                                    </content>
                                    <content styleCode="italics">)</content>
                                    <content styleCode="italics">].</content>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_89cf6b6f-f06d-4221-a414-403c10fb0732">
                     <id root="83ee5d89-2922-4c70-a43a-bc16d58d4f1d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7 Dose Modifications for Renal or Hepatic Impairment</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Moderate to Severe Renal Impairment or End Stage Renal Disease on Dialysis</content>
                        </paragraph>
                        <paragraph>Modify the Jakafi dosage for patients with moderate (CLcr 30 to 59 mL/min) to severe (CLcr 15 to 29 mL/min) renal impairment or end stage renal disease (ESRD) on dialysis according to Table 10. Avoid use of Jakafi in patients with ESRD (CLcr less than 15 mL/min) not requiring dialysis <content styleCode="italics">[see Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_3679786c-dc89-43d0-9583-dfa99e842ff9">8.6</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <table width="650px">
                           <caption>Table 10: Dose Modifications for Renal Impairment</caption>
                           <col/>
                           <col/>
                           <col/>
                           <tfoot>
                              <tr>
                                 <td valign="top" colspan="3" styleCode=" Toprule"> ESRD = end stage renal disease, and CLcr = creatinine clearance</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Renal Impairment Status</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Platelet Count</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Recommended Starting Dosage  </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Patients with MF</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Moderate or Severe</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">Greater than 150 x 10<sup>9</sup>/L</td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">No dose adjustment</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">100 to 150 x 10<sup>9</sup>/L</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">10 mg twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">50 to less than 100 x 10<sup>9</sup>/L</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">5 mg daily</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Less than 50 x 10<sup>9</sup>/L</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Avoid use <content styleCode="italics">[see Use in Specific <br/>
                                       </content>
                                       <content styleCode="italics">Populations (<linkHtml href="#LINK_3679786c-dc89-43d0-9583-dfa99e842ff9">8.6</linkHtml>)]</content>      </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>ESRD on dialysis</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">100 to 200 x 10<sup>9</sup>/L</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">15 mg once after dialysis session</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Greater than 200 x 10<sup>9</sup>/L</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">20 mg once after dialysis session</td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Patients with PV</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">Moderate or Severe	</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Any</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">5 mg twice daily</td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">ESRD on dialysis</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Any</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">10 mg once after dialysis session</td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Patients with aGVHD</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">Moderate or Severe</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Any</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">5 mg once daily</td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">ESRD on dialysis</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Any</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">5 mg once after dialysis session</td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Patients with cGVHD</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">Moderate or Severe <br/>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Any<br/>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">5 mg twice daily<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">ESRD on dialysis</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Any<br/>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">10 mg once after dialysis session<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>Modify the Jakafi dosage for patients with hepatic impairment according to Table 11.</paragraph>
                        <table width="650px">
                           <caption>Table 11: Dose Modifications for Hepatic Impairment</caption>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Hepatic Impairment Status</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Platelet Count             </content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Recommended Starting Dosage</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Patients with MF</content>
                                       <br/> Mild, Moderate, or Severe (Child-Pugh Class A, B, C)          	</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">Greater than 150 x 10<sup>9</sup>/L</td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">No dose adjustment</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">100 x 10<sup>9</sup>/L to 150 x 10<sup>9</sup>/L</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">10 mg twice daily </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">50 to less than 100 x 10<sup>9</sup>/L</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">5 mg daily </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Less than 50 x 10<sup>9</sup>/L</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Avoid use <content styleCode="italics">[see Use in Specific<br/>Populations (<linkHtml href="#www.splportal.comLINK_72d18376-7a08-4c26-b710-568c6b57a5a9">8.7</linkHtml>)]</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Patients with PV</content>
                                    <br/>Mild, Moderate, or Severe (Child-Pugh Class A, B, C)</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Any</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">5 mg twice daily</td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Patients with aGVHD</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Mild, Moderate, or Severe based on NCI criteria without liver GVHD</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Any</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">No dose adjustment</td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Stage 1, 2 or 3 Liver aGVHD<br/>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Any<br/>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">No dose adjustment<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Stage 4 Liver aGVHD</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Any</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">5 mg once daily</td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Patients with cGVHD</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Mild, Moderate, or Severe based on NCI criteria without liver GVHD</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Any</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">No dose adjustment<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Score 1 or 2 Liver cGVHD<br/>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Any</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">No dose adjustment<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Score 3 Liver cGVHD<br/>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Any</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Monitor blood counts more frequently for toxicity and modify the Jakafi dosage for adverse reactions if they occur <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_73306a47-692c-4d42-a8e9-a97fae787195">2.4</linkHtml>, <linkHtml href="#www.splportal.comLINK_f893c970-6c92-4300-90f7-cf44ab70cb9d">2.5</linkHtml>)]</content>.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_33090b69-42fc-4bc8-b30f-97962ed89b4e">
                     <id root="b87d0c99-75bf-4484-88cc-68f6fd5110bf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.8 Method of Administration</title>
                     <text>
                        <paragraph>Jakafi is dosed orally and can be administered with or without food.</paragraph>
                        <paragraph>If a dose is missed, the patient should not take an additional dose, but should take the next usual prescribed dose.</paragraph>
                        <paragraph>When discontinuing Jakafi therapy for reasons other than thrombocytopenia, gradual tapering of the dose of Jakafi may be considered, for example by 5 mg twice daily each week.</paragraph>
                        <paragraph>For patients unable to ingest tablets, Jakafi can be administered through a nasogastric tube (8 French or greater) as follows:</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Suspend one tablet in approximately 40 mL of water with stirring for approximately 10 minutes.</item>
                           <item>Within 6 hours after the tablet has dispersed, the suspension can be administered through a nasogastric tube using an appropriate syringe.</item>
                        </list>
                        <paragraph>The tube should be rinsed with approximately 75 mL of water. The effect of tube feeding preparations on Jakafi exposure during administration through a nasogastric tube has not been evaluated.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_1f7178bd-396b-4e97-81f3-662bb1034f3b">
               <id root="f6bb9a1f-383f-461b-89ef-9d52218c2258"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3. DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>5 mg tablets - round and white with "INCY" on one side and "5" on the other.</paragraph>
                  <paragraph>10 mg tablets - round and white with "INCY" on one side and "10" on the other.</paragraph>
                  <paragraph>15 mg tablets - oval and white with "INCY" on one side and "15" on the other.</paragraph>
                  <paragraph>20 mg tablets - capsule-shaped and white with "INCY" on one side and "20" on the other.</paragraph>
                  <paragraph>25 mg tablets - oval and white with "INCY" on one side and "25" on the other.</paragraph>
               </text>
               <effectiveTime value="20250624"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 5 mg, 10 mg, 15 mg, 20 mg and 25 mg. (<linkHtml href="#LINK_1f7178bd-396b-4e97-81f3-662bb1034f3b">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_93fc2181-fa99-4a78-b2e7-924c80fedabb">
               <id root="8cce97fd-3557-4980-96a0-cc2242e594af"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4. CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250624"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#LINK_93fc2181-fa99-4a78-b2e7-924c80fedabb">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_37e7976d-1ba9-475a-8309-3fabf2cef77d">
               <id root="1ec69007-f3ef-416d-a5f7-67e884bbe685"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5. WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20250624"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Thrombocytopenia, Anemia and Neutropenia: Manage by dose reduction, or interruption, or transfusion.  (<linkHtml href="#LINK_b4d13c83-97c5-4860-a1c6-04b5e89c93b1">5.1</linkHtml>)</item>
                           <item>Risk of Infection: Assess patients for signs and symptoms of infection and initiate appropriate treatment promptly. Serious infections should have resolved before starting therapy with Jakafi. (<linkHtml href="#LINK_4179c908-b0a4-444b-9c4c-a34b4adb23c6">5.2</linkHtml>)</item>
                           <item>Symptom Exacerbation Following Interruption or Discontinuation: Manage with supportive care and consider resuming treatment with Jakafi. (<linkHtml href="#LINK_213153e6-cdb7-4802-ac97-2bf7fa35d1c4">5.3</linkHtml>) </item>
                           <item> Risk of Non-Melanoma Skin Cancer: Perform periodic skin examinations. (<linkHtml href="#LINK_5a9727d3-1908-4d8e-9226-b2ba658fbf3e">5.4</linkHtml>)</item>
                           <item>Lipid Elevations: Assess lipid levels 8-12 weeks from start of therapy and treat as needed. (<linkHtml href="#LINK_448a0b1c-1ed2-414b-bd9c-aecb282f3605">5.5</linkHtml>)</item>
                           <item>Major Adverse Cardiovascular Events (MACE): Monitor for development of MACE. (<linkHtml href="#LINK_64e61648-9573-4ccd-8096-b44b152e882a">5.6</linkHtml>)<br/>
                           </item>
                           <item>Thrombosis: Evaluate and treat symptoms of thrombosis promptly. (<linkHtml href="#LINK_d29b847a-c2b8-43dd-a774-596da873afe7">5.7</linkHtml>)</item>
                           <item>Secondary Malignancies: Monitor for development of secondary malignancies, particularly in patients who are current or past smokers. (<linkHtml href="#LINK_a86af39d-03b9-43fc-9cb7-e3bc7370074d">5.8</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_b4d13c83-97c5-4860-a1c6-04b5e89c93b1">
                     <id root="7d17fa57-813f-4605-bc04-dfe37d170a8f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 		Thrombocytopenia, Anemia and Neutropenia</title>
                     <text>
                        <paragraph>Treatment with Jakafi can cause thrombocytopenia, anemia and neutropenia <content styleCode="italics">[</content>
                           <content styleCode="italics">see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_dec56268-7baf-4c87-b220-8131dc74d549">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>Manage thrombocytopenia by reducing the dose or temporarily interrupting Jakafi. Platelet transfusions may be necessary <content styleCode="italics">[</content>
                           <content styleCode="italics">see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_2757da7a-be91-4381-bd94-c7ea4a976fd2">2</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>Patients developing anemia may require blood transfusions and/or dose modifications of Jakafi.</paragraph>
                        <paragraph>Severe neutropenia (ANC less than 0.5 × 10<sup>9</sup>/L) was generally reversible by withholding Jakafi until recovery.</paragraph>
                        <paragraph>Perform a pre-treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated <content styleCode="italics">[</content>
                           <content styleCode="italics">see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_2757da7a-be91-4381-bd94-c7ea4a976fd2">2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4179c908-b0a4-444b-9c4c-a34b4adb23c6">
                     <id root="115b6abc-d4cd-45c4-965b-1ca09fb516ee"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 	Risk of Infection</title>
                     <text>
                        <paragraph>Serious bacterial, mycobacterial, fungal and viral infections have occurred <content styleCode="italics">[</content>
                           <content styleCode="italics">see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_dec56268-7baf-4c87-b220-8131dc74d549">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. Delay starting therapy with Jakafi until active serious infections have resolved. Observe patients receiving Jakafi for signs and symptoms of infection and manage promptly. Use active surveillance and prophylactic antibiotics according to clinical guidelines.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Tuberculosis</content>
                        </paragraph>
                        <paragraph>Tuberculosis infection has been reported in patients receiving Jakafi.  Observe patients receiving Jakafi for signs and symptoms of active tuberculosis and manage promptly.</paragraph>
                        <paragraph>Prior to initiating Jakafi, patients should be evaluated for tuberculosis risk factors, and those at higher risk should be tested for latent infection.  Risk factors include, but are not limited to, prior residence in or travel to countries with a high prevalence of tuberculosis, close contact with a person with active tuberculosis, and a history of active or latent tuberculosis where an adequate course of treatment cannot be confirmed.</paragraph>
                        <paragraph>For patients with evidence of active or latent tuberculosis, consult a physician with expertise in the treatment of tuberculosis before starting Jakafi.  The decision to continue Jakafi during treatment of active tuberculosis should be based on the overall risk-benefit determination.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Progressive Multifocal Leukoencephalopathy</content>
                        </paragraph>
                        <paragraph>Progressive multifocal leukoencephalopathy (PML) has occurred with Jakafi treatment. If PML is suspected, stop Jakafi and evaluate.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="xmChange">Herpes Zoster and Herpes Simplex</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Herpes zoster infection has been reported in patients receiving Jakafi <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_dec56268-7baf-4c87-b220-8131dc74d549">6.1</linkHtml>)]</content>. Advise patients about early signs and symptoms of herpes zoster and to seek treatment as early as possible if suspected.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Herpes simplex virus reactivation and/or dissemination has been reported in patients receiving Jakafi <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_ad27ba6a-8da6-479d-9dfa-18e2263be1f0">6.2</linkHtml>)]</content>. Monitor patients for the development of herpes simplex infections. If a patient develops evidence of dissemination of herpes simplex, consider interrupting treatment with Jakafi; patients should be promptly treated and monitored according to clinical guidelines.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatitis B</content>
                           <br/>
                        </paragraph>
                        <paragraph>Hepatitis B viral load (HBV-DNA titer) increases, with or without associated elevations in alanine aminotransferase and aspartate aminotransferase, have been reported in patients with chronic HBV infections taking Jakafi. The effect of Jakafi on viral replication in patients with chronic HBV infection is unknown. Patients with chronic HBV infection should be treated and monitored according to clinical guidelines.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_213153e6-cdb7-4802-ac97-2bf7fa35d1c4">
                     <id root="2c911ea2-672b-48ca-b12a-8681d73f23ae"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Symptom Exacerbation Following Interruption or Discontinuation of Treatment with Jakafi</title>
                     <text>
                        <paragraph>Following discontinuation of Jakafi, symptoms from myeloproliferative neoplasms may  return to pretreatment levels over a period of approximately one week.  Some patients with MF have experienced one or more of the following adverse events after discontinuing Jakafi:  fever, respiratory distress, hypotension, DIC, or multi-organ failure.  If one or more of these occur after discontinuation of, or while tapering the dose of Jakafi, evaluate for and treat any intercurrent illness and consider restarting or increasing the dose of Jakafi.  Instruct patients not to interrupt or discontinue Jakafi therapy without consulting their physician. When discontinuing or interrupting therapy with Jakafi for reasons other than thrombocytopenia or neutropenia <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_33090b69-42fc-4bc8-b30f-97962ed89b4e">2.8</linkHtml>)]</content>, consider tapering the dose of Jakafi gradually rather than discontinuing abruptly.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5a9727d3-1908-4d8e-9226-b2ba658fbf3e">
                     <id root="4f2f823f-7061-4a86-b56e-58371f050a10"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Non-Melanoma Skin Cancer (NMSC)</title>
                     <text>
                        <paragraph>Non-melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have occurred in patients treated with Jakafi.  Perform periodic skin examinations.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_448a0b1c-1ed2-414b-bd9c-aecb282f3605">
                     <id root="482d33a1-6ba0-49c8-9520-4688d2d60dfe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 

Lipid Elevations</title>
                     <text>
                        <paragraph>Treatment with Jakafi has been associated with increases in lipid parameters including total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_dec56268-7baf-4c87-b220-8131dc74d549">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. The effect of these lipid parameter elevations on cardiovascular morbidity and mortality has not been determined in patients treated with Jakafi. Assess lipid parameters approximately 8-12 weeks following initiation of Jakafi therapy. Monitor and treat according to clinical guidelines for the management of hyperlipidemia.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_64e61648-9573-4ccd-8096-b44b152e882a">
                     <id root="1045c0ca-5f77-49e1-8900-45a06419f986"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Major Adverse Cardiovascular Events (MACE)</title>
                     <text>
                        <paragraph>Another JAK-inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which Jakafi is not indicated.</paragraph>
                        <paragraph>Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with Jakafi particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d29b847a-c2b8-43dd-a774-596da873afe7">
                     <id root="2744d91b-dbfa-4d8c-8d7f-fcf1990ee8f1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Thrombosis</title>
                     <text>
                        <paragraph>Another JAK-inhibitor has increased the risk of thrombosis, including deep venous thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which Jakafi is not indicated. In patients with MF and PV treated with Jakafi in clinical trials, the rates of thromboembolic events were similar in Jakafi and control treated patients.</paragraph>
                        <paragraph>Patients with symptoms of thrombosis should be promptly evaluated and treated appropriately.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a86af39d-03b9-43fc-9cb7-e3bc7370074d">
                     <id root="9e9e7ca3-8f96-453c-8f40-269dab7b2bf6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Secondary Malignancies</title>
                     <text>
                        <paragraph>Another JAK-inhibitor has increased the risk of lymphoma and other malignancies excluding NMSC (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which Jakafi is not indicated. Patients who are current or past smokers are at additional increased risk.</paragraph>
                        <paragraph>Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with Jakafi, particularly in patients with a known secondary malignancy (other than a successfully treated NMSC), patients who develop a malignancy, and patients who are current or past smokers.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_0c8b404e-2eb5-4474-8467-7068d4cbf9e4">
               <id root="de3d1b71-a6d7-4fed-a0dd-e1208c2b9347"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6. ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Thrombocytopenia, Anemia and Neutropenia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_b4d13c83-97c5-4860-a1c6-04b5e89c93b1">5.1</linkHtml>)]</content>
                     </item>
                     <item>Risk of Infection <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_4179c908-b0a4-444b-9c4c-a34b4adb23c6">5.2</linkHtml>)]</content>
                     </item>
                     <item>Symptom Exacerbation Following Interruption or Discontinuation of Treatment with Jakafi <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_213153e6-cdb7-4802-ac97-2bf7fa35d1c4">5.3</linkHtml>)]</content>
                     </item>
                     <item>Non-Melanoma Skin Cancer <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_5a9727d3-1908-4d8e-9226-b2ba658fbf3e">5.4</linkHtml>)]</content>
                        <br/>
                     </item>
                     <item>Lipid Elevations <content styleCode="italics">[</content>
                        <content styleCode="italics">see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#www.splportal.comLINK_448a0b1c-1ed2-414b-bd9c-aecb282f3605">5.5</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Major Adverse Cardiovascular Events (MACE) <content styleCode="italics">[</content>
                        <content styleCode="italics">see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#www.splportal.comLINK_64e61648-9573-4ccd-8096-b44b152e882a">5.6</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Thrombosis <content styleCode="italics">[</content>
                        <content styleCode="italics">see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#www.splportal.comLINK_d29b847a-c2b8-43dd-a774-596da873afe7">5.7</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Secondary Malignancies <content styleCode="italics">[</content>
                        <content styleCode="italics">see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#www.splportal.comLINK_a86af39d-03b9-43fc-9cb7-e3bc7370074d">5.8</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250624"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>In myelofibrosis and polycythemia vera, the most common hematologic adverse reactions (incidence &gt; 20%) are thrombocytopenia and anemia. The most common nonhematologic adverse reactions (incidence ≥ 15%) are bruising, dizziness, headache, and diarrhea. (<linkHtml href="#LINK_dec56268-7baf-4c87-b220-8131dc74d549">6.1</linkHtml>)</item>
                           <item>In acute graft-versus-host disease, the most common hematologic adverse reactions (incidence &gt; 50%) are anemia, thrombocytopenia, and neutropenia. The most common nonhematologic adverse reactions (incidence &gt; 50%) are infections (pathogen not specified) and edema. (<linkHtml href="#LINK_dec56268-7baf-4c87-b220-8131dc74d549">6.1</linkHtml>)</item>
                           <item>In chronic graft-versus-host disease, the most common hematologic adverse reactions (incidence &gt; 35%) are anemia and thrombocytopenia. The most common nonhematologic adverse reactions (incidence ≥ 20%) are infections (pathogen not specified) and viral infections. (<linkHtml href="#LINK_dec56268-7baf-4c87-b220-8131dc74d549">6.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Incyte Corporation at 1-855-463-3463 or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="italics">
                              <content styleCode="underline">www.fda.gov/medwatch</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_dec56268-7baf-4c87-b220-8131dc74d549">
                     <id root="72bf3a22-16bd-49fa-8a17-19065a98b5cc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1	Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Myelofibrosis</content>
                        </paragraph>
                        <paragraph>The safety of Jakafi was assessed in 617 patients in six clinical studies with a median duration of follow-up of 10.9 months, including 301 patients with MF in two Phase 3 studies.</paragraph>
                        <paragraph>In these two Phase 3 studies, patients had a median duration of exposure to Jakafi of 9.5 months (range 0.5 to 17 months), with 89% of patients treated for more than 6 months and 25%  treated for more than 12 months. One hundred and eleven (111) patients started treatment at 15 mg twice daily and 190 patients started at 20 mg twice daily. In patients starting treatment with 15 mg twice daily (pretreatment platelet counts of 100 to 200 x 10<sup>9</sup>/L) and 20 mg twice daily (pretreatment platelet counts greater than 200 x 10<sup>9</sup>/L), 65% and 25% of patients, respectively, required a dose reduction below the starting dose within the first 8 weeks of therapy.</paragraph>
                        <paragraph>In a double-blind, randomized, placebo-controlled study of Jakafi, among the 155 patients treated with Jakafi, the most frequent adverse reactions were thrombocytopenia and anemia <content styleCode="italics">[see Table 13]</content>. Thrombocytopenia, anemia and neutropenia are dose-related effects. The three most frequent nonhematologic adverse reactions were bruising, dizziness and headache <content styleCode="italics">[see Table 12]</content>.</paragraph>
                        <paragraph>Discontinuation for adverse events, regardless of causality, was observed in 11% of patients treated with Jakafi and 11% of patients treated with placebo.</paragraph>
                        <paragraph>Table 12 presents the most common nonhematologic adverse reactions occurring in patients who received Jakafi in the double-blind, placebo-controlled study during randomized treatment.</paragraph>
                        <table width="675px">
                           <caption>Table 12: Myelofibrosis: Nonhematologic Adverse Reactions Occurring in Patients on Jakafi in the Double-blind, Placebo-controlled Study During Randomized Treatment</caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">  </td>
                                 <td align="center" colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Jakafi<br/>(N=155)</content>
                                 </td>
                                 <td align="center" colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Placebo<br/>(N=151)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Adverse Reactions</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">All<br/>Grades<footnote ID="FOOT_8368">National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0</footnote>
                                       <br/>(%)</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Grade 3
												<br/>(%)</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Grade 4
												<br/>(%)</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">All<br/>Grades
												<br/>(%)</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Grade 3
												<br/>(%)</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Grade 4
												<br/>(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Bruising<footnote ID="FOOT_22199">includes contusion, ecchymosis, hematoma, injection site hematoma, periorbital hematoma, vessel puncture site hematoma, increased tendency to bruise, petechiae, purpura</footnote> </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">23</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">15</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Dizziness<footnote ID="FOOT_22200">includes dizziness, postural dizziness, vertigo, balance disorder, Meniere’s Disease, labyrinthitis</footnote> </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">18</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">7</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Headache</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">15</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Urinary Tract Infections<footnote ID="FOOT_22201">includes urinary tract infection, cystitis, urosepsis, urinary tract infection bacterial, kidney infection, pyuria, bacteria urine, bacteria urine identified, nitrite urine present</footnote> </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">9</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Weight Gain<footnote ID="FOOT_21852">
                                       <paragraph>includes weight increased, abnormal weight gain</paragraph>
                                    </footnote> </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">7</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Flatulence</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Herpes Zoster<footnote ID="FOOT_21547">includes herpes zoster and post-herpetic neuralgia</footnote> </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">2</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Description of Selected Adverse Reactions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Anemia</content>
                        </paragraph>
                        <paragraph>In the two Phase 3 clinical studies, median time to onset of first CTCAE Grade 2 or higher anemia was approximately 6 weeks. One patient (&lt; 1%) discontinued treatment because of anemia. In patients receiving Jakafi, mean decreases in hemoglobin reached a nadir of approximately 1.5 to 2.0 g/dL below baseline after 8 to 12 weeks of therapy and then gradually recovered to reach a new steady state that was approximately 1.0 g/dL below baseline. This pattern was observed in patients regardless of whether they had received transfusions during therapy. </paragraph>
                        <paragraph>In the randomized, placebo-controlled study, 60% of patients treated with Jakafi and 38% of patients receiving placebo received red blood cell transfusions during randomized treatment. Among transfused patients, the median number of units transfused per month was 1.2 in patients treated with Jakafi and 1.7 in placebo treated patients.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Thrombocytopenia</content>
                        </paragraph>
                        <paragraph>In the two Phase 3 clinical studies, in patients who developed Grade 3 or 4 thrombocytopenia, the median time to onset was approximately 8 weeks. Thrombocytopenia was generally reversible with dose reduction or dose interruption. The median time to recovery of platelet counts above 50 x 10<sup>9</sup>/L was 14 days. Platelet transfusions were administered to 5% of patients receiving Jakafi and to 4% of patients receiving control regimens. Discontinuation of treatment because of thrombocytopenia occurred in &lt; 1% of patients receiving Jakafi and &lt; 1% of patients receiving control regimens. Patients with a platelet count of 100 x 10<sup>9</sup>/L to 200 x 10<sup>9</sup>/L before starting Jakafi had a higher frequency of Grade 3 or 4 thrombocytopenia compared to patients with a platelet count greater than 200 x 10<sup>9</sup>/L (17% versus 7%). </paragraph>
                        <paragraph>
                           <content styleCode="bold">Neutropenia</content>
                        </paragraph>
                        <paragraph>In the two Phase 3 clinical studies, 1% of patients reduced or stopped Jakafi because of neutropenia.</paragraph>
                        <paragraph>Table 13 provides the frequency and severity of clinical hematology abnormalities reported for patients receiving treatment with Jakafi or placebo in the placebo-controlled study.</paragraph>
                        <table>
                           <caption>Table 13: Myelofibrosis: Worst Hematology Laboratory Abnormalities in the Placebo-Controlled Study<footnote ID="FOOT_8362">
                                 <paragraph>Presented values are worst Grade values regardless of baseline</paragraph>
                              </footnote> </caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">  </td>
                                 <td align="center" colspan="3" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Jakafi<br/>(N=155)</content>
                                 </td>
                                 <td align="center" colspan="3" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Placebo<br/>(N=151)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Laboratory Parameter</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">All<br/>Grades<footnote ID="FOOT_8363">
                                          <paragraph>National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0</paragraph>
                                       </footnote> <br/>(%)</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Grade 3
												<br/>(%)</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Grade 4
												<br/>(%)</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">All<br/>Grades
												<br/>(%)</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Grade 3
												<br/>(%)</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Grade 4
												<br/>(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Thrombocytopenia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 70</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 9</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 4</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 31</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Anemia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 96</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 34</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 11</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 87</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 16</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 3</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Neutropenia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 19</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 5</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 2</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 4</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> &lt; 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 1</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Additional Data from the Placebo-Controlled Study</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>25% of patients treated with Jakafi and 7% of patients treated with placebo developed newly occurring or worsening Grade 1 abnormalities in alanine transaminase (ALT). The incidence of greater than or equal to Grade 2 elevations was 2% for Jakafi with 1% Grade 3 and no Grade 4 ALT elevations.</item>
                        </list>
                        <list listType="unordered" styleCode="Disk">
                           <item>17% of patients treated with Jakafi and 6% of patients treated with placebo developed newly occurring or worsening Grade 1 abnormalities in aspartate transaminase (AST). The incidence of Grade 2 AST elevations was &lt; 1% for Jakafi with no Grade 3 or 4 AST elevations.</item>
                        </list>
                        <list listType="unordered" styleCode="Disk">
                           <item>17% of patients treated with Jakafi and &lt; 1% of patients treated with placebo developed newly occurring or worsening Grade 1 elevations in cholesterol. The incidence of Grade 2 cholesterol elevations was &lt; 1% for Jakafi with no Grade 3 or 4 cholesterol elevations.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Polycythemia Vera</content>
                        </paragraph>
                        <paragraph>In a randomized, open-label, active-controlled study, 110 patients with PV resistant to or intolerant of hydroxyurea received Jakafi and 111 patients received best available therapy <content styleCode="italics">[see Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_ac90085e-3fbd-42b1-b15c-b87888766770">14.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. The most frequent adverse reaction was anemia. Discontinuation for adverse events, regardless of causality, was observed in 4% of patients treated with Jakafi. Table 14 presents the most frequent nonhematologic adverse reactions occurring up to Week 32.</paragraph>
                        <table width="675px">
                           <caption>Table 14: Polycythemia Vera: Nonhematologic Adverse Reactions Occurring in ≥ 5% of Patients on Jakafi in the Open-Label, Active-controlled Study up to Week 32 of Randomized Treatment</caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Jakafi<br/>(N=110)</content>
                                 </td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Best Available Therapy<br/>(N=111)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reactions<br/>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">All Grades<footnote ID="FOOT_22204">National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0</footnote>
                                       <br/>(%)</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Grade 3-4<br/>(%)</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">All Grades<br/>(%)</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Grade 3-4<br/>(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Diarrhea</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">15</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">7</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Dizziness<footnote ID="FOOT_8369">includes dizziness and vertigo</footnote> </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">15</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">13</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Dyspnea<footnote ID="FOOT_21546">includes dyspnea and dyspnea exertional</footnote> </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">13</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">3</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">4</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Muscle Spasms</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">12</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Constipation</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">8</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">3</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Herpes Zoster<footnote ID="FOOT_22202">includes herpes zoster and post-herpetic neuralgia</footnote> </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">6</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Nausea</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">6</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">4</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Weight Gain<footnote ID="FOOT_22203">includes weight increased and abnormal weight gain</footnote> </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">6</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Urinary Tract Infections<footnote ID="FOOT_21853">
                                       <paragraph>includes urinary tract infection and cystitis</paragraph>
                                    </footnote> </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">6</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">3</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Hypertension</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">3</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Clinically relevant laboratory abnormalities are shown in Table 15.</paragraph>
                        <table>
                           <caption>Table 15: Polycythemia Vera: Selected Laboratory Abnormalities in the Open-Label, Active-controlled Study up to Week 32 of Randomized Treatment<footnote ID="FOOT_20113">
                                 <paragraph>Presented values are worst Grade values regardless of baseline</paragraph>
                              </footnote> </caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td align="center" colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Jakafi<br/>(N=110)</content>
                                 </td>
                                 <td align="center" colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Best Available Therapy<br/>(N=111)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Laboratory Parameter</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">All<br/>Grades<footnote ID="FOOT_20114">
                                          <paragraph>National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0</paragraph>
                                       </footnote>
                                       <br/>(%)</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Grade 3<br/>(%)</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Grade 4<br/>(%)</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">All<br/>Grades<br/>(%)</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Grade 3<br/>(%)</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Grade 4<br/>(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="7" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Hematology</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Anemia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">72</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">58</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Thrombocytopenia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">27</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">24</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">3</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Neutropenia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">3</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">10</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td colspan="7" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Chemistry</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Hypercholesterolemia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">35</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">8</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Elevated ALT</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">25</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">16</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Elevated AST</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">23</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">23</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&lt; 1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Hypertriglyceridemia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">15</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">13</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Acute Graft-Versus-Host Disease</content>
                        </paragraph>
                        <paragraph>In a single-arm, open-label study, 71 adults (ages 18-73 years) were treated with Jakafi for aGVHD failing treatment with steroids with or without other immunosuppressive drugs <content styleCode="italics">[</content>see <content styleCode="italics">Clinical Studies </content>
                           <content styleCode="italics">(</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_467fa425-1da3-4967-a1df-ec35a63c848f">14.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. The median duration of treatment with Jakafi was 46 days (range, 4‑382 days).</paragraph>
                        <paragraph>There were no fatal adverse reactions to Jakafi. An adverse reaction resulting in treatment discontinuation occurred in 31% of patients. The most common adverse reaction leading to treatment discontinuation was infection (10%). Table 16 shows the adverse reactions other than laboratory abnormalities.</paragraph>
                        <table width="557.28px" cellspacing="0">
                           <caption>Table 16: Acute Graft-Versus-Host Disease: Nonhematologic Adverse Reactions Occurring in ≥ 15% of Patients in the Open-Label, Single-Cohort Study</caption>
                           <col width="179.57px"/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <br/>
                                 </td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Jakafi (N=71)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Adverse Reactions<footnote ID="FOOT_22938">Selected laboratory abnormalities are listed in Table 17 below</footnote> </content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">All Grades<footnote ID="FOOT_21332">National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03</footnote> </content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Grade 3-4<br/>(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Infections (pathogen not specified)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>55</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">41</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Edema</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">51</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">13</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Hemorrhage</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">49</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">20</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Fatigue</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">37</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">14</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Bacterial infections</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">32</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">28</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Dyspnea</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">32</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">7</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Viral infections</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">31</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">14</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Thrombosis</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">25</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">11</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Diarrhea</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">24</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">7</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Rash</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">23</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">3</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Headache</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">21</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">4</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Hypertension</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">20</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">13</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Dizziness</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">16</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Selected laboratory abnormalities during treatment with Jakafi are shown in Table 17.</paragraph>
                        <table width="471.54px">
                           <caption>Table 17: Acute Graft-Versus-Host Disease: Selected Laboratory Abnormalities Worsening from Baseline in the Open-Label, Single Cohort Study</caption>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Jakafi (N=71)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Worst grade during treatment</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Laboratory Parameter</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">All Grades<footnote ID="FOOT_22208">National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03</footnote>
                                       <br/>
                                       <content styleCode="bold">
                                          <sup>(%)</sup>
                                       </content>
                                    </content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Grade 3-4<br/>
                                          <content styleCode="bold">(%)</content>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Hematology</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Anemia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">75</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">45</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Thrombocytopenia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">75</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">61</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Neutropenia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">58</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">40</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Chemistry</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Elevated ALT</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">48</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">8</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Elevated AST</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">48</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">6</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Hypertriglyceridemia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">11</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Chronic Graft-Versus-Host Disease</content>
                        </paragraph>
                        <paragraph>In a Phase 3, randomized, open-label, multi-center study, 165 patients were treated with Jakafi and 158 patients were treated with best available therapy for cGVHD failing treatment with steroids with or without other immunosuppressive drugs <content styleCode="italics">[</content>
                           <content styleCode="italics">see Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_cd6ae4c0-804c-4c35-8d10-4ebbc6b6288e">14.4</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>; sixty-five patients crossed over from best available therapy to treatment with Jakafi, for a total of 230 patients treated with Jakafi. The median duration of exposure to Jakafi for the study was 49.7 weeks (range, 0.7 to 144.9 weeks) in the Jakafi arm. One hundred and nine (47%) patients were on Jakafi for at least 1 year. </paragraph>
                        <paragraph>There were five fatal adverse reactions to Jakafi, including 1 from toxic epidermal necrolysis and 4 from neutropenia, anemia and/or thrombocytopenia. An adverse reaction resulting in treatment discontinuation occurred in 18% of patients treated with Jakafi. An adverse reaction resulting in dose modification occurred in 27%, and an adverse reaction resulting in treatment interruption occurred in 23%. The most common hematologic adverse reactions (incidence &gt; 35%) are anemia and thrombocytopenia. The most common nonhematologic adverse reactions (incidence ≥ 20%) are infections (pathogen not specified) and viral infection.</paragraph>
                        <paragraph> Table 18 presents the most frequent nonlaboratory adverse reactions occurring up to Cycle 7 Day 1 of randomized treatment.</paragraph>
                        <table>
                           <caption>Table 18:	Chronic Graft-Versus-Host Disease: All-Grade (≥ 10%) and Grades 3-5 (≥ 3%) Nonlaboratory Adverse Reactions Occurring in Patients in the Open-Label, Active-controlled Study up to Cycle 7 Day 1 of Randomized Treatment</caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Adverse Reaction<footnote ID="FOOT_22944">Grouped terms that are composites of applicable adverse reaction terms.</footnote> </content>
                                    <br/>
                                 </td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Jakafi<br/> (N = 165)</content>
                                 </td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Best Available Therapy<br/> (N = 158)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">  All Grades<footnote ID="FOOT_22943">National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.03</footnote>   <br/>
                                       </content>
                                       <content styleCode="bold">(%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">  Grade ≥  3  <br/>
                                       </content>
                                       <content styleCode="bold">(%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">  All Grades  <br/>
                                       </content>
                                       <content styleCode="bold">(%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">  Grade </content>
                                       <content styleCode="bold">≥ 3  <br/>
                                       </content>
                                       <content styleCode="bold">(%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Infections and infestations</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">   Infections (pathogen not specified)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 45</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">15</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">44</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">16</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">   Viral infections<br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 28</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">23</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5</td>
                              </tr>
                              <tr>
                                 <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">   Musculoskeletal pain<br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">18</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">13</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">General disorders and administration site conditions</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">   Pyrexia<br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">16</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">2</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">9</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">   Fatigue<br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">13</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">10</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">2</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">   Edema</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">10</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">12</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1</td>
                              </tr>
                              <tr>
                                 <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Vascular disorders</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">   Hypertension<br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">16</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">13</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">7</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">   Hemorrhage<br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">12</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">2</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">15</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">2</td>
                              </tr>
                              <tr>
                                 <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">   Cough<br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">13</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">8</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">   Dyspnea<br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">11</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">8</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1</td>
                              </tr>
                              <tr>
                                 <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">   Nausea<br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">12</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">13</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">2</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">   Diarrhea<br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">10</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">13</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Clinically relevant laboratory abnormalities are shown in Table 19.</paragraph>
                        <table>
                           <caption>Table 19:	Chronic Graft-Versus-Host Disease: Selected Laboratory Abnormalities in the Open-Label, Active-controlled Study up to Cycle 7 Day 1 of Randomized Treatment<footnote ID="FOOT_22941">Presented values are worst Grade values regardless of baseline</footnote> </caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">
                                       <content styleCode="bold">Laboratory Test</content>
                                    </content>
                                    <br/>
                                 </td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Jakafi<br/>(N = 165)</content>
                                 </td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Best Available Therapy<br/>(N = 158)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">  All Grades<footnote ID="FOOT_22942">National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03</footnote>   <br/>
                                       </content>
                                       <content styleCode="bold">(%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">  Grade ≥ 3  <br/>
                                       </content>
                                       <content styleCode="bold">(%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">All Grades<br/>
                                       </content>
                                       <content styleCode="bold">(%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Grade </content>
                                       <content styleCode="bold">≥ 3<br/>
                                       </content>
                                       <content styleCode="bold">(%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">
                                       <content styleCode="bold">Hematology</content>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Anemia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">82</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">13</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">75</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">8</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Neutropenia<br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">27</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">12</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">23</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">9</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Thrombocytopenia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">58</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">20</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">54</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">17</td>
                              </tr>
                              <tr>
                                 <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">
                                       <content styleCode="bold">Chemistry</content>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Hypercholesterolemia<br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">88</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">10</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">85</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">8</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Elevated AST<br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">65</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">54</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">6</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Elevated ALT<br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">73</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">11</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">71</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">16</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Gamma glutamyltransferase increased         <br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">81</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">42</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">75</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">38</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Creatinine increased<br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">47</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">40</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">2</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Elevated lipase<br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">38</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">12</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">30</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">9</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Elevated amylase<br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">35</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">8</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">25</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">4</td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ad27ba6a-8da6-479d-9dfa-18e2263be1f0">
                     <id root="1f36d25d-b8aa-4b53-8d77-cc5674a2b2d2"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2	Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of Jakafi. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Infections and Infestations: Herpes simplex virus reactivation and/or dissemination</item>
                        </list>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_af04531c-2dc2-45cb-bcd6-83d16e2c9b33">
               <id root="2c8cf314-396c-4252-aae6-152e8ce1af7b"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7. DRUG INTERACTIONS</title>
               <text/>
               <effectiveTime value="20250624"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item> Fluconazole: Avoid concomitant use with fluconazole doses greater than 200 mg. Reduce Jakafi dosage with fluconazole doses less than or equal to 200 mg. (<linkHtml href="#LINK_be19d915-2084-4e5a-905e-54d7e9de7464">2.6</linkHtml>, <linkHtml href="#LINK_af04531c-2dc2-45cb-bcd6-83d16e2c9b33">7</linkHtml>)</item>
                           <item>Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue Jakafi doses as recommended except in patients with acute or chronic graft-versus-host-disease. (<linkHtml href="#LINK_be19d915-2084-4e5a-905e-54d7e9de7464">2.6</linkHtml>, <linkHtml href="#LINK_af04531c-2dc2-45cb-bcd6-83d16e2c9b33">7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_40664de0-d265-49b0-8835-f77b95eee7f8">
                     <id root="a85c0ad9-1629-4db2-977b-45370ff3df09"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Effect of Other Drugs on Jakafi</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Fluconazole</content>
                        </paragraph>
                        <paragraph>Concomitant use of Jakafi with fluconazole increases ruxolitinib exposure <content styleCode="italics">[</content>
                           <content styleCode="italics">see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_f448284e-b9ff-4b27-aa48-f06c45a3f159">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>, which may increase the risk of exposure-related adverse reactions. Avoid concomitant use of Jakafi with fluconazole doses of greater than 200 mg daily. Reduce the Jakafi dosage when used concomitantly with fluconazole doses of less than or equal to 200 mg <content styleCode="italics">[</content>
                           <content styleCode="italics">see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_be19d915-2084-4e5a-905e-54d7e9de7464">2.6</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Strong CYP3A4 Inhibitors</content>
                        </paragraph>
                        <paragraph>Concomitant use of Jakafi with strong CYP3A4 inhibitors increases ruxolitinib exposure <content styleCode="italics">[</content>
                           <content styleCode="italics">see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_f448284e-b9ff-4b27-aa48-f06c45a3f159">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>, which may increase the risk of exposure-related adverse reactions. Reduce the Jakafi dosage when used concomitantly with strong CYP3A4 inhibitors except in patients with aGVHD or cGVHD <content styleCode="italics">[</content>
                           <content styleCode="italics">see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_be19d915-2084-4e5a-905e-54d7e9de7464">2.6</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Strong CYP3A4 Inducers</content>
                        </paragraph>
                        <paragraph>Concomitant use of Jakafi with strong CYP3A4 inducers may decrease ruxolitinib exposure <content styleCode="italics">[</content>
                           <content styleCode="italics">see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_f448284e-b9ff-4b27-aa48-f06c45a3f159">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>, which may reduce efficacy of Jakafi. Monitor patients frequently and adjust the Jakafi dose based on safety and efficacy <content styleCode="italics">[</content>
                           <content styleCode="italics">see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_f448284e-b9ff-4b27-aa48-f06c45a3f159">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_8f2503ed-f6e6-479d-a575-63137ebc1380">
               <id root="3f139049-ce56-42e6-b9ad-b9bdc39dab35"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8. USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20250624"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Renal Impairment: Reduce Jakafi starting dose or avoid treatment as recommended. (<linkHtml href="#LINK_89cf6b6f-f06d-4221-a414-403c10fb0732">2.7</linkHtml>, <linkHtml href="#LINK_3679786c-dc89-43d0-9583-dfa99e842ff9">8.6</linkHtml>)</item>
                           <item>Hepatic Impairment: Reduce Jakafi starting dose or avoid treatment as recommended.  (<linkHtml href="#LINK_89cf6b6f-f06d-4221-a414-403c10fb0732">2.7</linkHtml>, <linkHtml href="#LINK_72d18376-7a08-4c26-b710-568c6b57a5a9">8.7</linkHtml>)</item>
                           <item>Lactation: Advise not to breastfeed. (<linkHtml href="#LINK_14b3e03f-dc0f-4268-bee2-ee4f26c085a9">8.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_3738e690-1f44-41cc-9a95-da0c35a3124b">
                     <id root="54de0158-77b0-4dbf-b2a7-53b9db8a0c6e"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 		Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Risk Summary</content>
                        </paragraph>
                        <paragraph>When pregnant rats and rabbits were administered ruxolitinib during the period of organogenesis adverse developmental outcomes occurred at doses associated with maternal toxicity (<content styleCode="italics">see Data</content>). There are no studies with the use of Jakafi in pregnant women to inform drug-associated risks. </paragraph>
                        <paragraph>The background risk of major birth defects and miscarriage for the indicated populations is unknown. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. The background risk in the U.S. general population of major birth defects is 2% to 4% and miscarriage is 15% to 20% of clinically recognized pregnancies.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Ruxolitinib was administered orally to pregnant rats or rabbits during the period of organogenesis, at doses of 15, 30 or 60 mg/kg/day in rats and 10, 30 or 60 mg/kg/day in rabbits. There were no treatment-related malformations. Adverse developmental outcomes, such as decreases of approximately 9% in fetal weights were noted in rats at the highest and maternally toxic dose of 60 mg/kg/day. This dose results in an exposure (AUC) that is approximately 2 times the clinical exposure at the maximum recommended dose of 25 mg twice daily. In rabbits, lower fetal weights of approximately 8% and increased late resorptions were noted at the highest and maternally toxic dose of 60 mg/kg/day. This dose is approximately 7% the clinical exposure at the maximum recommended dose.</paragraph>
                        <paragraph>In a pre- and post-natal development study in rats, pregnant animals were dosed with ruxolitinib from implantation through lactation at doses up to 30 mg/kg/day. There were no drug-related adverse findings in pups for fertility indices or for maternal or embryofetal survival, growth and development parameters at the highest dose evaluated (34% the clinical exposure at the maximum recommended dose of 25 mg twice daily).</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_14b3e03f-dc0f-4268-bee2-ee4f26c085a9">
                     <id root="9970b5f0-d30f-45c0-a8ca-7d2ae2156b89"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Risk Summary</content>
                        </paragraph>
                        <paragraph>No data are available regarding the presence of ruxolitinib in human milk, the effects on the breast fed child, or the effects on milk production. Ruxolitinib and/or its metabolites were present in the milk of lactating rats (<content styleCode="italics">see Data</content>). Because many drugs are present in human milk and because of the potential for thrombocytopenia and anemia shown for Jakafi in human studies, discontinue breastfeeding during treatment with Jakafi and for two weeks after the final dose. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Lactating rats were administered a single dose of [<sup>14</sup>C]-labeled ruxolitinib (30 mg/kg) on postnatal Day 10, after which plasma and milk samples were collected for up to 24 hours. The AUC for total radioactivity in milk was approximately 13-fold the maternal plasma AUC. Additional analysis showed the presence of ruxolitinib and several of its metabolites in milk, all at levels higher than those in maternal plasma.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1e070251-5f67-4d69-96fc-ab3f45393625">
                     <id root="9eb479e0-a9fb-4af8-a657-37c2e1348d34"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 		Pediatric Use</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Myelofibrosis</content>
                        </paragraph>
                        <paragraph>The safety and effectiveness of Jakafi for treatment of myelofibrosis in pediatric patients have not been established.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Polycythemia Vera</content>
                        </paragraph>
                        <paragraph>The safety and effectiveness of Jakafi for treatment of polycythemia vera in pediatric patients have not been established.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Acute Graft-Versus-Host Disease</content>
                        </paragraph>
                        <paragraph>The safety and effectiveness of Jakafi for treatment of steroid-refractory aGVHD has been established for treatment of pediatric patients 12 years and older. Use of Jakafi in pediatric patients with steroid-refractory aGVHD is supported by evidence from adequate and well-controlled trials of Jakafi in adults <content styleCode="italics">[</content>
                           <content styleCode="italics">see Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_467fa425-1da3-4967-a1df-ec35a63c848f">14.3</linkHtml>
                           </content>
                           <content styleCode="italics">)] </content>and additional pharmacokinetic and safety data in pediatric patients. The safety and effectiveness of Jakafi for treatment of steroid-refractory aGVHD has not been established in pediatric patients younger than 12 years old.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Chronic Graft-Versus-Host Disease</content>
                        </paragraph>
                        <paragraph>The safety and effectiveness of Jakafi for treatment of cGVHD after failure of one or two lines of systemic therapy has been established for treatment of pediatric patients 12 years and older. Use of Jakafi in pediatric patients with cGVHD after failure of one or two lines of systemic therapy is supported by evidence from adequate and well-controlled trials of Jakafi in adults and adolescents <content styleCode="italics">[</content>
                           <content styleCode="italics">see Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_cd6ae4c0-804c-4c35-8d10-4ebbc6b6288e">14.4</linkHtml>
                           </content>
                           <content styleCode="italics">)] </content>and additional pharmacokinetic and safety data in pediatric patients. The safety and effectiveness of Jakafi for treatment of cGVHD has not been established in pediatric patients younger than 12 years old.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Other Myeloproliferative Neoplasms, Leukemias, and Solid Tumors</content>
                        </paragraph>
                        <paragraph>The safety and effectiveness of ruxolitinib were assessed but not established in a single-arm trial (NCT01164163) in patients with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms. The patients included 18 children (age 2 to &lt; 12 years) and 14 adolescents (age 12 to &lt; 17 years). Overall, 19% of patients received more than one cycle. No new safety signals were observed in pediatric patients in this trial.</paragraph>
                        <paragraph>The safety and effectiveness of ruxolitinib in combination with chemotherapy for treatment of high-risk, de novo CRLF2 rearranged or JAK pathway–mutant Ph-like acute lymphoblastic leukemia (ALL) were assessed but not established in a single-arm trial (NCT02723994). The patients included 2 infants (age &lt; 2 years), 42 children (age 2 to &lt; 12 years) and 62 adolescents (age 12 to &lt; 17 years). No new safety signals were observed in pediatric patients in this trial.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Juvenile Animal Toxicity Data</content>
                        </paragraph>
                        <paragraph>Administration of ruxolitinib to juvenile rats resulted in effects on growth and bone measures. When administered starting at postnatal day 7 (the equivalent of a human newborn) at doses of 1.5 to 75 mg/kg/day, evidence of fractures occurred at doses ≥ 30 mg/kg/day, and effects on body weight and other bone measures [e.g., bone mineral content, peripheral quantitative computed tomography, and x-ray analysis] occurred at doses ≥ 5 mg/kg/day. When administered starting at postnatal day 21 (the equivalent of a human 2-3 years of age) at doses of 5 to 60 mg/kg/day, effects on body weight and bone occurred at doses ≥ 15 mg/kg/day, which were considered adverse at 60 mg/kg/day. Males were more severely affected than females in all age groups, and effects were generally more severe when administration was initiated earlier in the postnatal period. These findings were observed at exposures that are at least 27% the clinical exposure at the maximum recommended dose of 25 mg twice daily. </paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3c5e1a2b-ee7e-4b51-a7e7-55ada3e979f4">
                     <id root="e240f0dc-861b-46ca-873c-40c9e58d7473"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 		Geriatric Use</title>
                     <text>
                        <paragraph>Of the total number of patients with MF in clinical studies with Jakafi, 52% were 65 years and older, while 15% were 75 years and older. No overall differences in safety or effectiveness of Jakafi were observed between these patients and younger patients.</paragraph>
                        <paragraph>Clinical studies of Jakafi in patients with aGVHD did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger subjects.</paragraph>
                        <paragraph> Of the total number of patients with cGVHD treated with Jakafi in clinical trials, 11% were 65 years and older. No overall differences in safety or effectiveness of Jakafi were observed between these patients and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3679786c-dc89-43d0-9583-dfa99e842ff9">
                     <id root="5225057f-1a7c-413f-b793-6d03db407751"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 		Renal Impairment</title>
                     <text>
                        <paragraph>Total exposure of ruxolitinib and its active metabolites increased with moderate (CLcr 30 to 59 mL/min) and severe (CLcr 15 to 29 mL/min) renal impairment, and ESRD (CLcr less than 15 mL/min) on dialysis <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_f448284e-b9ff-4b27-aa48-f06c45a3f159">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. Modify Jakafi dosage as recommended <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_89cf6b6f-f06d-4221-a414-403c10fb0732">2.7</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_72d18376-7a08-4c26-b710-568c6b57a5a9">
                     <id root="b81862a4-68f4-48b8-9eea-117062f56246"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 		Hepatic Impairment</title>
                     <text>
                        <paragraph>Exposure of ruxolitinib increased with mild (Child-Pugh A), moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_f448284e-b9ff-4b27-aa48-f06c45a3f159">12.3</linkHtml>)]</content>.<br/>
                        </paragraph>
                        <paragraph>Reduce Jakafi dosage as recommended in patients with MF or PV with hepatic impairment <content styleCode="italics">[</content>
                           <content styleCode="italics">see </content>
                           <content styleCode="italics">Dosage and Administration (<linkHtml href="#www.splportal.comLINK_89cf6b6f-f06d-4221-a414-403c10fb0732">2.7</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>
                           <content styleCode="italics">. </content>Reduce Jakafi dosage as recommended for patients with Stage 4 liver aGVHD.<br/>
                        </paragraph>
                        <paragraph> Monitor blood counts more frequently for toxicity and modify the Jakafi dosage for adverse reactions if they occur for patients with Score 3 liver cGVHD <content styleCode="italics">[</content>
                           <content styleCode="italics">see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_89cf6b6f-f06d-4221-a414-403c10fb0732">2.7</linkHtml>
                           </content>
                           <content styleCode="italics">) and Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_f448284e-b9ff-4b27-aa48-f06c45a3f159">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_17210849-4a6f-44f5-a1d9-7406393bebdc">
               <id root="d0fe4ca6-d3d4-4bbf-b18a-1a998cf07118"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10. OVERDOSAGE</title>
               <text>
                  <paragraph>There is no known antidote for overdoses with Jakafi. Single doses up to 200 mg have been given with acceptable acute tolerability. Higher than recommended repeat doses are associated with increased myelosuppression including leukopenia, anemia and thrombocytopenia. Appropriate supportive treatment should be given.</paragraph>
                  <paragraph>Hemodialysis is not expected to enhance the elimination of Jakafi.</paragraph>
               </text>
               <effectiveTime value="20250624"/>
            </section>
         </component>
         <component>
            <section ID="LINK_c3e16042-df70-4a0b-9bc8-6ddb2d4fbc03">
               <id root="c655ca29-2e93-47f1-a7cd-19610492a513"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11. DESCRIPTION</title>
               <text>
                  <paragraph>Ruxolitinib phosphate is a kinase inhibitor with the chemical name (<content styleCode="italics">R</content>)-3-(4-(7<content styleCode="italics">H</content>-pyrrolo[2,3-<content styleCode="italics">d</content>]pyrimidin-4-yl)-1<content styleCode="italics">H</content>-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and a molecular weight of 404.36. Ruxolitinib phosphate has the following structural formula:</paragraph>
                  <paragraph> <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Ruxolitinib phosphate is a white to off-white to light pink powder and is soluble in aqueous buffers across a pH range of 1 to 8. </paragraph>
                  <paragraph>Jakafi (ruxolitinib) Tablets are for oral administration. Each tablet contains 6.6 mg, 13.2 mg, 19.8 mg, 26.4 mg, or 33 mg of ruxolitinib phosphate equivalent to 5 mg, 10 mg, 15 mg, 20 mg, or 25 mg of ruxolitinib free base, respectively, together with microcrystalline cellulose, lactose monohydrate, magnesium stearate, colloidal silicon dioxide, sodium starch glycolate, povidone and hydroxypropyl cellulose.</paragraph>
               </text>
               <effectiveTime value="20250624"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Ruxolitinib phosphate structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="jakafi-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_8d1726b4-48ff-43e2-be4d-771a5f6d2916">
               <id root="120001ce-3411-44f2-8a26-2da514f257eb"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12. CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250624"/>
               <component>
                  <section ID="LINK_4a0a83b7-cc4c-4402-98da-840da6fab057">
                     <id root="4dfec0b8-6fe0-4d35-84c4-fcf6ba2e44b9"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 	Mechanism of Action</title>
                     <text>
                        <paragraph>Ruxolitinib, a kinase inhibitor, inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. JAK signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation and subsequent localization of STATs to the nucleus leading to modulation of gene expression.</paragraph>
                        <paragraph>MF and PV are myeloproliferative neoplasms (MPN) known to be associated with dysregulated JAK1 and JAK2 signaling. In a mouse model of JAK2V617F-positive MPN, oral administration of ruxolitinib prevented splenomegaly, preferentially decreased JAK2V617F mutant cells in the spleen and decreased circulating inflammatory cytokines (e.g., TNF-α, IL-6).</paragraph>
                        <paragraph>JAK-STAT signaling pathways play a role in regulating the development, proliferation, and activation of several immune cell types important for GVHD pathogenesis. In a mouse model of aGVHD, oral administration of ruxolitinib was associated with decreased expression of inflammatory cytokines in colon homogenates and reduced immune-cell infiltration in the colon.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e47c47f7-5a1a-406f-ac09-a23d7afdff09">
                     <id root="5e203f8c-528b-4c4c-9a0b-500a29d16939"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Jakafi inhibits cytokine induced STAT3 phosphorylation in whole blood from patients with MF and PV. STAT3 phosphorylation reached maximal inhibition 2 hours after Jakafi dosing and returned to near baseline by 10 hours in patients with MF and PV. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>At a dose of 1.25 to 10 times the highest recommended starting dosage, Jakafi does not prolong the QT interval to any clinically relevant extent.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f448284e-b9ff-4b27-aa48-f06c45a3f159">
                     <id root="e542071a-01cc-421e-ac45-cde06c75ea98"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 		Pharmacokinetics</title>
                     <text>
                        <paragraph>Mean ruxolitinib maximal plasma concentration (C<sub>max</sub>) and AUC increased proportionally over a single dose range of 5 mg to 200 mg (4 times the approved highest recommended total daily dosage of 25 mg twice daily). Mean ruxolitinib C<sub>max</sub> ranged from 205 nM to 7100 nM and AUC ranged from 862 nM*hr to 30700 nM*hr over a single dose range of 5 mg to 200 mg.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Absorption</content>
                        </paragraph>
                        <paragraph>Ruxolitinib achieves C<sub>max</sub> within 1 hour to 2 hours post-dose. Oral absorption of ruxolitinib is estimated to be at least 95%. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Food</content>
                        </paragraph>
                        <paragraph>No clinically relevant changes in the pharmacokinetics of ruxolitinib were observed upon administration of Jakafi with a high-fat, high-calorie meal (approximately 800 to 1000 calories of which 50% were derived from fat). </paragraph>
                        <paragraph>
                           <content styleCode="bold">Distribution</content>
                        </paragraph>
                        <paragraph>The mean ruxolitinib volume of distribution at steady-state is 72 L (coefficient of variation [CV] 29%) in patients with MF and 75 L (23%) in patients with PV. </paragraph>
                        <paragraph> Protein binding of ruxolitinib is approximately 97%, mostly to albumin. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Elimination</content>
                        </paragraph>
                        <paragraph>The mean elimination half-life of ruxolitinib is approximately 3 hours and the mean elimination half-life of ruxolitinib and its metabolites is approximately 5.8 hours in healthy volunteers. </paragraph>
                        <paragraph>Ruxolitinib clearance (%CV) was 17.7 L/h in women and 22.1 L/h in men with MF (39%).</paragraph>
                        <paragraph>Ruxolitinib clearance (%CV) was 12.7 L/h (42%) in patients with PV.</paragraph>
                        <paragraph>Ruxolitinib clearance (%CV) was 11.8 L/h (63%) in patients with aGVHD.</paragraph>
                        <paragraph>Ruxolitinib clearance (%CV) was 9.7 L/h (51%) in patients with cGVHD.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Ruxolitinib is metabolized by CYP3A4 and to a lesser extent by CYP2C9.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph> Following a single oral dose of radiolabeled ruxolitinib, 74% of radioactivity was excreted in urine and 22% via feces. Unchanged drug accounted for less than 1% of the excreted total radioactivity. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Specific Populations</content>
                        </paragraph>
                        <paragraph>No clinically relevant differences in ruxolitinib pharmacokinetics were observed based on age (12-73 years), race (White, Asian), sex, or weight (29-139 kg). </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment</content>
                        </paragraph>
                        <paragraph>Total AUC of ruxolitinib and its active metabolites increased by 1.3-, 1.5-, 1.9-, and 1.6-fold in subjects with mild, moderate, severe renal impairment, and with ESRD after dialysis, respectively, compared to subjects with normal renal function (CLcr ≥ 90 mL/min). The change in the pharmacodynamic marker, pSTAT3 inhibition, was consistent with the corresponding increase in metabolite exposure with renal impairment. Ruxolitinib is not removed by dialysis; however, the removal of some active metabolites by dialysis cannot be ruled out.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>No clinically relevant effect on ruxolitinib pharmacokinetics was observed based on mild to severe hepatic impairment by NCI criteria (total bilirubin &gt; ULN and any AST) in patients with aGVHD or cGVHD.</paragraph>
                        <paragraph>Ruxolitinib AUC increased in subjects with mild (Child-Pugh A) by 1.9-fold, moderate (Child-Pugh B) by 1.3-fold, and severe (Child-Pugh C) hepatic impairment by 1.7-fold compared to that in subjects with normal hepatic function.</paragraph>
                        <paragraph>The change in the pharmacodynamic marker, pSTAT3 inhibition, was consistent with the corresponding increase in ruxolitinib exposure except in the severe hepatic impairment cohort where the pharmacodynamic activity was more prolonged in some subjects than expected based on plasma concentrations of ruxolitinib.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Liver Involvement in Graft-Versus-Host Disease</content>
                        </paragraph>
                        <paragraph>No clinically relevant effect on ruxolitinib pharmacokinetics was observed based on Stage 1, 2 or 3 liver aGVHD, or Score 1, or 2 liver cGVHD. </paragraph>
                        <paragraph>A lower apparent clearance of ruxolitinib was observed in patients with Stage 4 liver aGVHD compared to patients with no liver aGVHD.</paragraph>
                        <paragraph> The effect of Score 3 liver cGVHD on the pharmacokinetics of ruxolitinib is unknown.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Clinical Studies and Model-Informed Approaches </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Fluconazole</content>: Fluconazole 100 to 400 mg once daily (a moderate CYP3A4 and CYP2C9 inhibitor) increases steady state ruxolitinib AUC by approximately 100% to 300% <content styleCode="italics">[</content>
                           <content styleCode="italics">see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_be19d915-2084-4e5a-905e-54d7e9de7464">2.6</linkHtml>
                           </content>
                           <content styleCode="italics">) and Drug Interactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_af04531c-2dc2-45cb-bcd6-83d16e2c9b33">7</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Strong CYP3A4 inhibitors</content>: Ketoconazole (strong CYP3A4 inhibitor) increased ruxolitinib C<sub>max </sub>by 33% and AUC by 91% and prolonged ruxolitinib half-life from 3.7 hours to 6 hours <content styleCode="italics">[</content>
                           <content styleCode="italics">see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_be19d915-2084-4e5a-905e-54d7e9de7464">2.6</linkHtml>
                           </content>
                           <content styleCode="italics">) and Drug Interactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_af04531c-2dc2-45cb-bcd6-83d16e2c9b33">7</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Moderate CYP3A4 inhibitors</content>: Erythromycin (moderate CYP3A4 inhibitor) increased ruxolitinib C<sub>max </sub>by 8% and AUC by 27% <content styleCode="italics">[</content>
                           <content styleCode="italics">see Drug Interactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_af04531c-2dc2-45cb-bcd6-83d16e2c9b33">7</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Strong CYP3A4 inducers</content>: Rifampin (strong CYP3A4 inducer) decreased ruxolitinib C<sub>max </sub>by 32% and AUC by 61%. The relative exposure to ruxolitinib’s active metabolites increased approximately 100% <content styleCode="italics">[</content>
                           <content styleCode="italics">see Drug Interactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_af04531c-2dc2-45cb-bcd6-83d16e2c9b33">7</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vitro Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cytochrome P450 (CYP) Enzymes</content>: Ruxolitinib and its M18 metabolite did not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4. Ruxolitinib did not induce CYP1A2, CYP2B6 or CYP3A4 at clinically relevant concentrations.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Transporter Systems</content>: Ruxolitinib and its M18 metabolite did not inhibit the P-gp, BCRP, OATP1B1, OATP1B3, OCT1, OCT2, OAT1 or OAT3 at clinically relevant concentrations. Ruxolitinib was not a P-gp substrate.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_8a4ff39b-98af-497a-a510-a75aaec91406">
               <id root="cde595c5-b800-4281-b3e4-898564e3f7cb"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13. NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250624"/>
               <component>
                  <section ID="LINK_966f8179-d191-4281-aef4-228382908c1a">
                     <id root="f58bfa2b-0c38-4efd-88b9-ebbed9090ec9"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Ruxolitinib was not carcinogenic in the 6-month Tg.rasH2 transgenic mouse model or in a 2-year carcinogenicity study in the rat.</paragraph>
                        <paragraph>Ruxolitinib was not mutagenic in a bacterial mutagenicity assay (Ames test) or clastogenic in <content styleCode="italics">in vitro</content> chromosomal aberration assay (cultured human peripheral blood lymphocytes) or <content styleCode="italics">in vivo</content> in a rat bone marrow micronucleus assay.</paragraph>
                        <paragraph>In a fertility study, ruxolitinib was administered to male rats prior to and throughout mating and to female rats prior to mating and up to the implantation day (gestation day 7). Ruxolitinib had no effect on fertility or reproductive function in male or female rats at doses of 10, 30 or 60 mg/kg/day. However, in female rats doses of greater than or equal to 30 mg/kg/day resulted in increased post-implantation loss. The exposure (AUC) at the dose of 30 mg/kg/day is approximately 34% the clinical exposure at the maximum recommended dose of 25 mg twice daily.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_35a6eeb6-afb3-467a-9164-284eb045a6ee">
               <id root="17ed3c95-b9d0-4878-85a1-6de34b849950"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14. CLINICAL STUDIES</title>
               <effectiveTime value="20250624"/>
               <component>
                  <section ID="LINK_5a5b83a1-ec09-4f61-b812-9fc2457d5ecb">
                     <id root="ac4ef82e-0d99-47c6-ab6e-fbe55556bd1b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Myelofibrosis</title>
                     <text>
                        <paragraph>Two randomized Phase 3 studies (Studies 1 and 2) were conducted in patients with MF (either primary MF, post-polycythemia vera MF or post-essential thrombocythemia-MF). In both studies, patients had palpable splenomegaly at least 5 cm below the costal margin and risk category of intermediate 2 (2 prognostic factors) or high risk (3 or more prognostic factors) based on the International Working Group Consensus Criteria (IWG).</paragraph>
                        <paragraph>The starting dose of Jakafi was based on platelet count. Patients with a platelet count between 100 and 200 x 10<sup>9</sup>/L were started on Jakafi 15 mg twice daily and patients with a platelet count greater than 200 x 10<sup>9</sup>/L were started on Jakafi 20 mg twice daily. Doses were then individualized based upon tolerability and efficacy with maximum doses of 20 mg twice daily for patients with platelet counts between 100 to less than or equal to 125 x 10<sup>9</sup>/L, of 10 mg twice daily for patients with platelet counts between 75 to less than or equal to 100 x 10<sup>9</sup>/L, and of 5 mg twice daily for patients with platelet counts between 50 to less than or equal to 75 x 10<sup>9</sup>/L.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Study 1 </content>
                        </paragraph>
                        <paragraph>Study 1 (NCT00952289) was a double-blind, randomized, placebo-controlled study in 309 patients who were refractory to or were not candidates for available therapy. The median age was 68 years (range 40 to 91 years) with 61% of patients older than 65 years and 54% were male. Fifty percent (50%) of patients had primary MF, 31% had post-polycythemia vera MF and 18% had post-essential thrombocythemia MF. Twenty-one percent (21%) of patients had red blood cell transfusions within 8 weeks of enrollment in the study. The median hemoglobin count was 10.5 g/dL and the median platelet count was 251 x 10<sup>9</sup>/L. Patients had a median palpable spleen length of 16 cm below the costal margin, with 81% having a spleen length 10 cm or greater below the costal margin. Patients had a median spleen volume as measured by magnetic resonance imaging (MRI) or computed tomography (CT) of 2595 cm<sup>3</sup> (range 478 cm<sup>3</sup> to 8881 cm<sup>3</sup>). (The upper limit of normal is approximately 300 cm<sup>3</sup>).</paragraph>
                        <paragraph>Patients were dosed with Jakafi or matching placebo. The primary efficacy endpoint was the proportion of patients achieving greater than or equal to a 35% reduction from baseline in spleen volume at Week 24 as measured by MRI or CT.</paragraph>
                        <paragraph>Secondary endpoints included duration of a 35% or greater reduction in spleen volume and proportion of patients with a 50% or greater reduction in Total Symptom Score from baseline to Week 24 as measured by the modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 diary.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Study 2</content>
                        </paragraph>
                        <paragraph>Study 2 (NCT00934544) was an open-label, randomized study in 219 patients. Patients were randomized 2:1 to Jakafi versus best available therapy. Best available therapy was selected by the investigator on a patient-by-patient basis. In the best available therapy arm, the medications received by more than 10% of patients were hydroxyurea (47%) and glucocorticoids (16%). The median age was 66 years (range 35 to 85 years) with 52% of patients older than 65 years and 57% were male. Fifty-three percent (53%) of patients had primary MF, 31% had post-polycythemia vera MF and 16% had post-essential thrombocythemia MF. Twenty-one percent (21%) of patients had red blood cell transfusions within 8 weeks of enrollment in the study. The median hemoglobin count was 10.4 g/dL and the median platelet count was 236 x 10<sup>9</sup>/L. Patients had a median palpable spleen length of 15 cm below the costal margin, with 70% having a spleen length 10 cm or greater below the costal margin. Patients had a median spleen volume as measured by MRI or CT of 2381 cm<sup>3</sup> (range 451 cm<sup>3</sup> to 7765 cm<sup>3</sup>).</paragraph>
                        <paragraph>The primary efficacy endpoint was the proportion of patients achieving 35% or greater reduction from baseline in spleen volume at Week 48 as measured by MRI or CT.</paragraph>
                        <paragraph>A secondary endpoint in Study 2 was the proportion of patients achieving a 35% or greater reduction of spleen volume as measured by MRI or CT from baseline to Week 24.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Study 1 and 2 Efficacy Results</content>
                        </paragraph>
                        <paragraph>Efficacy analyses of the primary endpoint in Studies 1 and 2 are presented in Table 20 below.  A significantly larger proportion of patients in the Jakafi group achieved a 35% or greater reduction in spleen volume from baseline in both studies compared to placebo in Study 1 and best available therapy in Study 2. A similar proportion of patients in the Jakafi group achieved a 50% or greater reduction in palpable spleen length.</paragraph>
                        <table>
                           <caption>Table 20: Percent of Patients with Myelofibrosis Achieving 35% or Greater Reduction from Baseline in Spleen Volume at Week 24 in Study 1 and at Week 48 in Study 2 (Intent to Treat)</caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">  </td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Study 1</content>
                                 </td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Study 2</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">  </td>
                                 <td align="center" valign="bottom" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Jakafi<br/>(N=155)</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Placebo<br/>(N=154)</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Jakafi<br/>(N=146)</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Best Available<br/>Therapy<br/>(N=73)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Time Points</td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Week 24</td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Week 48</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Number (%) of Patients with <br/>Spleen Volume Reduction by <br/>35% or More</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">      65 (42)     </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">      1 (&lt; 1)     </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">      41 (29)     </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">      0     </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">P-value</td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> &lt; 0.0001</td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> &lt; 0.0001</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Figure 1 shows the percent change from baseline in spleen volume for each patient at Week 24 (Jakafi N=139, placebo N=106) or the last evaluation prior to Week 24 for patients who did not complete 24 weeks of randomized treatment (Jakafi N=16, placebo N=47). One (1) patient (placebo) with a missing baseline spleen volume is not included.</paragraph>
                        <renderMultiMedia referencedObject="MM2"/>
                        <paragraph>In Study 1, MF symptoms were a secondary endpoint and were measured using the modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 diary. The modified MFSAF is a daily diary capturing the core symptoms of MF (abdominal discomfort, pain under left ribs, night sweats, itching, bone/muscle pain and early satiety). Symptom scores ranged from 0 to 10 with 0 representing symptoms "absent" and 10 representing "worst imaginable" symptoms. These scores were added to create the daily total score, which has a maximum of 60.</paragraph>
                        <paragraph>Table 21 presents assessments of Total Symptom Score from baseline to Week 24 in Study 1 including the proportion of patients with at least a 50% reduction (ie, improvement in symptoms). At baseline, the mean Total Symptom Score was 18.0 in the Jakafi group and 16.5 in the placebo group. A higher proportion of patients in the Jakafi group had a 50% or greater reduction in Total Symptom Score than in the placebo group, with a median time to response of less than 4 weeks.</paragraph>
                        <table width="600px">
                           <caption>Table 21: Improvement in Total Symptom Score in Patients with Myelofibrosis</caption>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">  </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Jakafi
												<br/>(N=148)</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Placebo
												<br/>(N=152)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Number (%) of Patients with 50% or Greater Reduction <br/>in Total Symptom Score by Week 24</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">        68 (46)       </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">        8 (5)       </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">P-value</td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> &lt; 0.0001</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Figure 2 shows the percent change from baseline in Total Symptom Score for each patient at Week 24 (Jakafi N=129, placebo N=103) or the last evaluation on randomized therapy prior to Week 24 for patients who did not complete 24 weeks of randomized treatment (Jakafi N=16, placebo N=42). Results are excluded for 5 patients with a baseline Total Symptom Score of zero, 8 patients with missing baseline and 6 patients with insufficient post-baseline data.</paragraph>
                        <renderMultiMedia referencedObject="MM3"/>
                        <paragraph>Figure 3 displays the proportion of patients with at least a 50% improvement in each of the individual symptoms that comprise the Total Symptom Score indicating that all 6 of the symptoms contributed to the higher Total Symptom Score response rate in the group treated with Jakafi.</paragraph>
                        <renderMultiMedia referencedObject="MM4"/>
                        <paragraph>An exploratory analysis of patients receiving Jakafi also showed improvement in fatigue-related symptoms (i.e., tiredness, exhaustion, mental tiredness, and lack of energy) and associated impacts on daily activities (i.e., activity limitations related to work, self-care, and exercise) as measured by the PROMIS<sup>®</sup> Fatigue 7-item short form total score at Week 24. Patients who achieved a reduction of 4.5 points or more from baseline to Week 24 in the PROMIS<sup>®</sup> Fatigue total score were considered to have achieved a fatigue response. Fatigue response was reported in 35% of patients in the Jakafi group versus 14% of the patients in the placebo group.</paragraph>
                        <paragraph>Overall survival was a secondary endpoint in both Study 1 and Study 2. Patients in the control groups were eligible for crossover in both studies, and the median times to crossover were 9 months in Study 1 and 17 months in Study 2.</paragraph>
                        <paragraph>Figure 4 and Figure 5 show Kaplan-Meier curves of overall survival at prospectively planned analyses after all patients remaining on study had completed 144 weeks on study.</paragraph>
                        <renderMultiMedia referencedObject="MM5"/>
                        <renderMultiMedia referencedObject="MM6"/>
                     </text>
                     <effectiveTime value="20250624"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>Percent Change from Baseline in Spleen Volume at Week 24 or Last Observation for Each Patient (Study 1)</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="jakafi-2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM3">
                           <text>Percent Change from Baseline in Total Symptom Score at Week 24 or Last Observation for Each Patient (Study 1)</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="jakafi-3.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM4">
                           <text>Proportion of Patients with Myelofibrosis Achieving 50% or Greater Reduction in Individual Symptom Scores at Week 24</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="jakafi-4.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM5">
                           <text>Overall Survival - Kaplan-Meier Curves by Treatment Group in Study 1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="jakafi-5.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM6">
                           <text>Overall Survival - Kaplan Meier Curves by Treatment Group in Study 2</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="jakafi-6.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ac90085e-3fbd-42b1-b15c-b87888766770">
                     <id root="6b63f005-8689-4c2b-8b2c-674a2858f5d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2	Polycythemia Vera</title>
                     <text>
                        <paragraph>Study 3 (NCT01243944) was a randomized, open-label, active-controlled Phase 3 study conducted in 222 patients with PV. Patients had been diagnosed with PV for at least 24 weeks, had an inadequate response to or were intolerant of hydroxyurea, required phlebotomy and exhibited splenomegaly.  All patients were required to demonstrate hematocrit control between 40-45% prior to randomization. The age ranged from 33 to 90 years with 30% of patients over 65 years of age and 66% were male.  Patients had a median spleen volume as measured by MRI or CT of 1272 cm<sup>3</sup> (range 254 cm<sup>3</sup> to 5147 cm<sup>3</sup>) and median palpable spleen length below the costal margin was 7 cm.</paragraph>
                        <paragraph>Patients were randomized to Jakafi or best available therapy. The starting dose of Jakafi was 10 mg twice daily. Doses were then individualized based upon tolerability and efficacy with a maximum dose of 25 mg twice daily. At Week 32, 98 patients were still on Jakafi with 8% receiving greater than 20 mg twice daily, 15% receiving 20 mg twice daily, 33% receiving 15 mg twice daily, 34% receiving 10 mg twice daily, and 10% receiving less than 10 mg twice daily. Best available therapy (BAT) was selected by the investigator on a patient-by-patient basis and included hydroxyurea (60%), interferon/pegylated interferon (12%), anagrelide (7%), pipobroman (2%), lenalidomide/thalidomide (5%), and observation (15%).</paragraph>
                        <paragraph>The primary endpoint was the proportion of subjects achieving a response at Week 32, with response defined as having achieved both hematocrit control (the absence of phlebotomy eligibility  beginning at the Week 8 visit and continuing through Week 32) and spleen volume  reduction (a greater than or equal to 35% reduction from baseline in spleen volume at Week 32). Phlebotomy eligibility was defined as a confirmed hematocrit greater than 45% that is at least 3 percentage points higher than the hematocrit obtained at baseline or a confirmed hematocrit greater than 48%, whichever was lower.  Secondary endpoints included the proportion of all randomized subjects who achieved the primary endpoint and who maintained their response 48 weeks after randomization, and the proportion of subjects achieving complete hematological remission at Week 32 with complete hematological remission defined as achieving hematocrit control, platelet count less than or equal to 400 x 10<sup>9</sup>/L, and white blood cell count less than or equal to 10 x 10<sup>9</sup>/L.</paragraph>
                        <paragraph>Results of the primary and secondary endpoints are presented in Table 22. A significantly larger proportion of patients on the Jakafi arm achieved a response for the primary endpoint compared to best available therapy at Week 32 and maintained their response 48 weeks after randomization. A significantly larger proportion of patients on the Jakafi arm compared to best available therapy also achieved complete hematological remission at Week 32.</paragraph>
                        <table width="75%">
                           <caption>Table 22: Percent of Patients with Polycythemia Vera Achieving the Primary and Key Secondary Endpoints in Study 3 (Intent to Treat)</caption>
                           <col width="40%"/>
                           <col width="30%"/>
                           <col width="30%"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3">Primary Response defined as having achieved both the absence of phlebotomy eligibility beginning at the Week 8 visit and continuing through Week 32 and a greater than or equal to 35% reduction from baseline in spleen volume at Week 32.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold"> Jakafi<br/>(N=110)</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold"> Best Available<br/>Therapy<br/>(N=112)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Number (%) of Patients Achieving a Primary Response at Week 32 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 25 (23%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 1 (&lt; 1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">95% CI of the response rate (%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> (15%, 32%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> (0%, 5%)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">P-value</td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> &lt; 0.0001</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Number (%) of Patients Achieving a Durable Primary Response at Week 48</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 22 (20%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 1 (&lt; 1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">95% CI of the response rate (%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> (13%, 29%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> (0%, 5%)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">P-value</td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> &lt; 0.0001</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Number (%) of Patients Achieving Complete Hematological Remission at Week 32</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 26 (24%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">9 (8%)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">95% CI of the response rate (%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> (16%, 33%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> (4%, 15%)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">P-value</td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> 0.0016</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Additional analyses for Study 3 to assess durability of response were conducted at Week 80 only in the Jakafi arm. On this arm, 91 (83%) patients were still on treatment at the time of the Week 80 data cut-off. Of the 25 patients who achieved a primary response at Week 32, 19 (76% of the responders) maintained their response through Week 80, and of the 26 patients who achieved complete hematological remission at Week 32, 15 (58% of the responders) maintained their response through Week 80.  </paragraph>
                        <paragraph>In an assessment of the individual components that make up the primary endpoint, there were 66 (60%) patients with hematocrit control on the Jakafi arm vs. 21 (19%) patients on best available therapy at Week 32; 51 (77% of hematocrit responders) patients on the Jakafi arm maintained hematocrit control through Week 80. There were 44 (40%) patients with spleen volume reduction from baseline greater than or equal to 35% on the Jakafi arm vs. 1 (&lt; 1%) patient on best available therapy at Week 32; 43 (98% of spleen volume reduction responders) patients on the Jakafi arm maintained spleen volume reduction through Week 80.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_467fa425-1da3-4967-a1df-ec35a63c848f">
                     <id root="4a356f29-9ec5-469a-b15f-425200c5c8f8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3

Acute Graft-Versus-Host Disease</title>
                     <text>
                        <paragraph>Study 4 (NCT02953678) was an open-label, single-arm, multicenter study of Jakafi for treatment of patients with steroid-refractory aGVHD Grades 2 to 4 (Mount Sinai Acute GVHD International Consortium (MAGIC) criteria) occurring after allogeneic hematopoietic stem cell transplantation. Jakafi was administered at 5 mg twice daily, and the dose could be increased to 10 mg twice daily after 3 days in the absence of toxicity.  </paragraph>
                        <paragraph>There were 49 patients with aGVHD refractory to steroids alone. These patients had a median age of 57 years (range, 18-72 years), 47% were male, 92% were Caucasian, and 14% were Hispanic. At baseline, aGVHD was Grade 2 in 27%, Grade 3 in 55%, and Grade 4 in 18%; 84% had visceral GVHD; the median MAGIC biomarker score was 0.47 (range, 0.10‑0.92); and the median ST2 level was 334 mcg/L (range, 55-1286 mcg/L). The median duration of prior corticosteroid exposure at baseline was 15 days (range: 3 - 106 days).  </paragraph>
                        <paragraph> The efficacy of Jakafi was based on Day-28 overall response rate (ORR) (complete response, very good partial response or partial response by Center for International Blood and Marrow Transplant Research (CIBMTR) criteria) and the duration of response. The ORR results are presented in Table 23; Day-28 ORR was 100% for Grade 2 GVHD, 40.7% for Grade 3 GVHD, and 44.4% for Grade 4 GVHD. </paragraph>
                        <paragraph>The median duration of response, calculated from Day-28 response to progression, new salvage therapy for aGVHD or death from any cause (with progression being defined as worsening by one stage in any organ without improvement in other organs in comparison to prior response assessment) was 16 days (95% CI 9, 83). Also, for the Day-28 responders, the median time from Day-28 response to either death or need for new therapy for aGVHD (additional salvage therapy or increase in steroids) was 173 days (95% CI 66, NE).</paragraph>
                        <table width="55%">
                           <caption>Table 23: Day-28 Overall Response Rate for Patients with Steroid-Refractory Acute GVHD in Study 4</caption>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Refractory to Steroids Alone<br/>(n=49)</content> </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Overall Response (%) (95% CI)</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">28 (57.1%) (42.2, 71.2)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Complete Response</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">15 (30.6%)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Very Good Partial Response</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">2 (4.1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Partial Response</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">11 (22.4%)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_cd6ae4c0-804c-4c35-8d10-4ebbc6b6288e">
                     <id root="e41ad955-5526-4346-bdfe-d04700ffa661"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.4 Chronic Graft-Versus-Host Disease</title>
                     <text>
                        <paragraph>Study 5 (REACH-3; NCT03112603) was a randomized, open-label, multicenter study of Jakafi in comparison to best available therapy (BAT) for treatment of corticosteroid-refractory cGVHD after allogeneic stem cell transplantation. Eligible patients were ≥ 12 years old with moderate or severe cGVHD as defined by NIH Consensus Criteria requiring additional therapy after failure of corticosteroid therapy and no more than one additional salvage treatment. Patients were excluded if they had ANC &lt; 1 Gi/L and platelet count &lt; 25 Gi/L, estimated creatinine clearance &lt; 30 ml/min, progressive onset cGVHD, oxygen saturation &lt; 90%, total bilirubin &gt; 2 mg/dL, or diarrhea due to GVHD. </paragraph>
                        <paragraph> A total of 329 patients were randomized 1:1 to receive either Jakafi 10 mg twice daily (n=165) or BAT (n=164). BAT was selected by the investigator prior to randomization and included the following treatments: extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, or ibrutinib. Randomization was stratified by cGVHD severity (moderate versus severe). On Cycle 7 Day 1 and thereafter, patients randomized to BAT could cross over to Jakafi if they had disease progression, mixed response, unchanged response, cGVHD flare, or toxicity to BAT. All patients also received standard supportive care, including anti-infective medications. GVHD prophylaxis and cGVHD treatment medications initiated before randomization, including systemic corticosteroids, calcineurin inhibitors, and topical or inhaled corticosteroid therapy, were allowed to be continued per institutional guidelines. Table 24 shows the demographics and baseline disease characteristics of the randomized population.</paragraph>
                        <table>
                           <caption>Table 24:	REACH-3: Demographics and Baseline Chronic GVHD Characteristics</caption>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">       Jakafi       <br/>
                                       </content>
                                       <content styleCode="bold">(N=165)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">    Best Available Therapy    <br/>
                                       </content>
                                       <content styleCode="bold">(N=164)</content> </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Median Age, Years (range)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 49 (13, 73)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">50 (12, 76)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>      Age 12 to &lt; 18 Year, n (%)<br/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 4 (2)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 8 (5)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>      Age &gt; 65 Years, n (%)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 18 (11)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 22 (13)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Male, n (%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 109 (66)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 92 (56)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Race, n (%)</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>      White</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 116 (70)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 132 (81)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>      Black</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 2 (1)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>      Asian</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 33 (20)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 21 (13)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>      American Indian or Alaska native</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 2 (1)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>      Other</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 9 (6)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 4 (2)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>      Unknown</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 3 (2)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 7 (4)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Median (range) time (days) from cGVHD diagnosis to randomization       </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 174 (7-2017)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 150 (10-1947)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Prior Therapy</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>      No prior treatment for cGVHD</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 2 (1)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 1 (1)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>      Failed first-line steroids alone</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 115 (70)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 125 (76)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>      Failed first-line combination including steroids</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 42 (25)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 30 (18)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>      Failed two lines of therapy</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 6 (4)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 8 (5)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> ≥ 4 Organs involved, n (%) </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 67 (41)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 63 (38)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Severe cGVHD, n (%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 86 (52)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 79 (48)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Median (range) cGVHD Total Symptom Score</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 19 (0-80)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 18 (1-54)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Median (range) corticosteroid dose at baseline (PE mg/kg)<footnote ID="FOOT_22940">Prednisone equivalent milligrams/kilogram</footnote> </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">   0.29 (0.01-1.81)   </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">   0.26 (0.06-1.21)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The efficacy of Jakafi was based on overall response rate (ORR) through Cycle 7 Day 1, where overall response included complete response or partial response according to the 2014 NIH Response Criteria and durability of the response. The ORR results are presented in Table 25; the difference in ORR between Jakafi and BAT arms was 13% (95% CI 3%, 23%). The median time to first response in the responders was 3 weeks (range, 2 to 24) for the Jakafi arm and 4 weeks (range, 2 to 25) for the BAT arm. The median duration of response, calculated from first response to progression, death, or new systemic therapies for cGVHD, was 4.2 months (95% CI 3.2, 6.7) for the Jakafi arm and 2.1 months (95% CI 1.6, 3.2) for the BAT arm; and the median time from first response to death or new systemic therapies for cGVHD was 25 months (95% CI 16.8, NE) for the Jakafi arm and 5.6 months (95% CI 4.1, 7.8) for the BAT arm.</paragraph>
                        <table>
                           <caption>Table 25:	Overall Response Rate through Cycle 7 Day 1 for Patients with Chronic GVHD in Study 5</caption>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold"> Jakafi<br/> (N=165)</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Best Available Therapy<br/> (N=164) </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Overall Response (%) </content>
                                    <br/>
                                    <content styleCode="bold">(95% CI)<footnote ID="FOOT_22939">95% CI of Overall Response Rate is estimated using Clopper-Pearson method.</footnote> </content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">      116 (70%)<br/>     (63%, 77%)     </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 94 (57%)<br/> (49%, 65%)</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">      <content styleCode="bold">Complete Response (%)       </content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 14 (8%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 8 (5%)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">      Partial Response (%)</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 102 (62%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 86 (52%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>ORR results were supported by exploratory analyses of patient-reported symptom severity which showed at least a 7-point decrease in the cGVHD Total Symptom Score at any time through Cycle 7 Day 1 in 66 (40%; 95% CI 32, 48) patients in the Jakafi arm and 47 (29%; 95% CI 22, 36) patients in the BAT arm.</paragraph>
                     </text>
                     <effectiveTime value="20250624"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_a982bce8-0e4d-486c-b810-3c9d1371d94a">
               <id root="437dfdb8-f35d-4e8b-b2af-94b76f4aac43"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16. HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Jakafi (ruxolitinib) Tablets are available as follows:</paragraph>
                  <table width="650px">
                     <caption>Jakafi Trade Presentations</caption>
                     <col width="120px"/>
                     <col width="85px"/>
                     <col width="250px"/>
                     <col width="120px"/>
                     <tfoot>
                        <tr>
                           <td colspan="4">Store at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">NDC Number</content>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Strength</content>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Description </content>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Tablets per<br/>Bottle</content> </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">50881-005-60</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">5 mg</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Round tablet with “INCY” on one side and “5” on the other </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">60 </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">50881-010-60</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">10 mg</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Round tablet with “INCY” on one side and “10” on the other</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">60 </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">50881-015-60</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">15 mg</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Oval tablet with “INCY” on one side and “15” on the other</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">60 </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">50881-020-60</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">20 mg</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Capsule-shaped tablet with “INCY” on one side and “20” on the other</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">60 </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">50881-025-60</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">25 mg</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Oval tablet with “INCY” on one side and “25” on the other</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">60 </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250624"/>
            </section>
         </component>
         <component>
            <section ID="LINK_d7721e16-b4dd-4846-b5e1-7544e6ab169d">
               <id root="c3bc8472-1adf-4b86-9d45-d3d914b3b88f"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17. PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Thrombocytopenia, Anemia and Neutropenia</content>
                  </paragraph>
                  <paragraph>Inform patients that Jakafi is associated with thrombocytopenia, anemia and neutropenia, and of the need to monitor complete blood counts before and during treatment.  Advise patients to observe for and report bleeding <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#www.splportal.comLINK_b4d13c83-97c5-4860-a1c6-04b5e89c93b1">5.1</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Infections</content>
                  </paragraph>
                  <paragraph>Inform patients of the signs and symptoms of infection and to report any such signs and symptoms promptly.</paragraph>
                  <paragraph>Inform patients regarding the early signs and symptoms of herpes zoster and of progressive multifocal leukoencephalopathy, and advise patients to seek advice of a clinician if such symptoms are observed <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#www.splportal.comLINK_4179c908-b0a4-444b-9c4c-a34b4adb23c6">5.2</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Symptom Exacerbation Following Interruption or Discontinuation of Treatment with Jakafi</content>
                  </paragraph>
                  <paragraph>Inform patients that after discontinuation of treatment, signs and symptoms from myeloproliferative neoplasms are expected to return.  Instruct patients not to interrupt or discontinue Jakafi therapy without consulting their physician <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#www.splportal.comLINK_213153e6-cdb7-4802-ac97-2bf7fa35d1c4">5.3</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Non-Melanoma Skin Cancer</content>
                  </paragraph>
                  <paragraph>Inform patients that Jakafi may increase their risk of certain non-melanoma skin cancers.  Advise patients to inform their healthcare provider if they have ever had any type of skin cancer or if they observe any new or changing skin lesions <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#www.splportal.comLINK_5a9727d3-1908-4d8e-9226-b2ba658fbf3e">5.4</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lipid Elevations</content>
                  </paragraph>
                  <paragraph>Inform patients that Jakafi may increase blood cholesterol, and of the need to monitor blood cholesterol levels <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#www.splportal.comLINK_448a0b1c-1ed2-414b-bd9c-aecb282f3605">5.5</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Major Adverse Cardiovascular Events (MACE)</content>
                  </paragraph>
                  <paragraph>Advise patients that events of major adverse cardiovascular events (MACE) including myocardial infarction, stroke, and cardiovascular death, have been reported in clinical studies with another JAK-inhibitor used to treat rheumatoid arthritis, a condition for which Jakafi is not indicated. Advise patients, especially current or past smokers or patients with other cardiovascular risk factors, to be alert for the development of signs and symptoms of cardiovascular events <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#www.splportal.comLINK_64e61648-9573-4ccd-8096-b44b152e882a">5.6</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Thrombosis </content>
                  </paragraph>
                  <paragraph>Advise patients that events of DVT and PE have been reported in clinical studies with another JAK-inhibitor used to treat rheumatoid arthritis, a condition for which Jakafi is not indicated. Advise patients to tell their healthcare provider if they develop any signs or symptoms of a DVT or PE <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#www.splportal.comLINK_d29b847a-c2b8-43dd-a774-596da873afe7">5.7</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Secondary Malignancies</content>
                  </paragraph>
                  <paragraph> Advise patients, especially current or past smokers and patients with a known secondary malignancy (other than a successfully treated NMSC), that lymphoma and other malignancies (excluding NMSC) have been reported in clinical studies with another JAK-inhibitor used to treat rheumatoid arthritis, a condition for which Jakafi is not indicated <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#www.splportal.comLINK_a86af39d-03b9-43fc-9cb7-e3bc7370074d">5.8</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Drug-Drug Interactions</content>
                  </paragraph>
                  <paragraph>Advise patients to inform their healthcare providers of all medications they are taking, including over-the-counter medications, herbal products and dietary supplements <content styleCode="italics">[see Drug Interactions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#www.splportal.comLINK_40664de0-d265-49b0-8835-f77b95eee7f8">7.1</linkHtml>
                     </content>
                     <content styleCode="italics">) and Clinical Pharmacology (</content>
                     <content styleCode="italics">
                        <linkHtml href="#www.splportal.comLINK_f448284e-b9ff-4b27-aa48-f06c45a3f159">12.3</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Dialysis</content>
                  </paragraph>
                  <paragraph>Inform patients on dialysis that their dose should not be taken before dialysis but only following dialysis <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_89cf6b6f-f06d-4221-a414-403c10fb0732">2.7</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph> Inform women not to breastfeed during treatment with Jakafi and for two weeks after the final dose <content styleCode="italics">[see Use in Specific Populations (</content>
                     <content styleCode="italics">
                        <linkHtml href="#www.splportal.comLINK_14b3e03f-dc0f-4268-bee2-ee4f26c085a9">8.2</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Compliance</content>
                  </paragraph>
                  <paragraph>Advise patients to continue taking Jakafi every day for as long as their physician tells them and that this is a long-term treatment. Patients should not change dose or stop taking Jakafi without first consulting their physician. Patients should be aware that after discontinuation of treatment, signs and symptoms from myeloproliferative neoplasms are expected to return. </paragraph>
                  <paragraph>Manufactured for:<br/>
							Incyte Corporation<br/>1801 Augustine Cut-off<br/>Wilmington, DE 19803
     	</paragraph>
                  <paragraph>Jakafi is a registered trademark of Incyte. All rights reserved.<br/>U.S. Patent Nos. 7598257; 8415362; 8722693; 8822481; 8829013; 9079912; 9814722; 10016429<br/>© 2011-2023 Incyte Corporation. All rights reserved.</paragraph>
               </text>
               <effectiveTime value="20250624"/>
            </section>
         </component>
         <component>
            <section ID="LINK_b6c36b05-eb36-4192-8a39-518433fa4328">
               <id root="be050dbe-b545-4201-8c9d-341b169e2f7a"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title/>
               <text>
                  <table width="100%">
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Patient Information<br/>JAKAFI<sup>®</sup> (JAK-ah-fye)</content>
                                 <br/>(ruxolitinib)<br/>
                                 <content styleCode="bold">tablets<br/>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What is Jakafi?</content>
                              </paragraph>
                              <paragraph>Jakafi is a prescription medicine used to treat: </paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>adults with certain types of myelofibrosis (MF).</item>
                                 <item>adults with polycythemia vera (PV) who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.</item>
                                 <item>adults and children 12 years of age and older with acute graft-versus-host-disease (aGVHD) who have taken corticosteroids and they did not work well enough.</item>
                                 <item>adults and children 12 years of age and older with chronic graft-versus-host-disease (cGVHD) who have taken one or two types of treatments and they did not work well enough.</item>
                              </list>
                              <paragraph>It is not known if Jakafi is safe or effective in children for treatment of myelofibrosis or polycythemia vera.   </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Before taking Jakafi, tell your healthcare provider about of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>have an infection</item>
                                 <item>have or have had low white or red blood cell counts</item>
                                 <item>have or had tuberculosis (TB), or have been in close contact with someone who has TB</item>
                                 <item>have had shingles (herpes zoster)</item>
                                 <item>have or had hepatitis B</item>
                                 <item>have or have had liver problems</item>
                                 <item>have or have had kidney problems or are on dialysis. If you are on dialysis, Jakafi should be taken after your dialysis.</item>
                                 <item>have a high level of fat in your blood (high blood cholesterol or triglycerides) </item>
                                 <item>have had cancer in the past</item>
                                 <item>are a current or past smoker</item>
                                 <item>have had a blood clot, heart attack, other heart problems or stroke</item>
                                 <item>are pregnant or plan to become pregnant. It is not known if Jakafi will harm your unborn baby. </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if Jakafi passes into your breast milk. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins and herbal supplements. Taking Jakafi with certain other medicines may affect how Jakafi works. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.    </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">How should I take Jakafi?</content>
                              <list listType="unordered" styleCode="Disk">
                                 <item>Take Jakafi exactly as your healthcare provider tells you.</item>
                                 <item>Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.</item>
                                 <item>You can take Jakafi with or without food.</item>
                                 <item>Jakafi may also be given through certain nasogastric tubes. <list listType="unordered" styleCode="Circle">
                                       <item>Tell your healthcare provider if you cannot take Jakafi by mouth. Your healthcare provider will decide if you can take Jakafi through a nasogastric tube.</item>
                                       <item>Ask your healthcare provider to give you specific instruction on how to properly take Jakafi through a nasogastric tube.</item>
                                    </list>
                                 </item>
                                 <item>If you miss a dose of Jakafi, take your next dose at your regular time. Do not take 2 doses at the same time.</item>
                                 <item>If you take too much Jakafi call your healthcare provider or go to the nearest hospital emergency room right away. </item>
                                 <item>You will have regular blood tests during your treatment with Jakafi. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests.        </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of Jakafi?<br/>
                                    <br/>
                                 </content>
                                 <content styleCode="bold">Jakafi can cause serious side effects including:<br/>
                                    <br/>
                                 </content>
                                 <content styleCode="bold">Low blood cell counts.</content> Jakafi may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia). If you develop bleeding, stop Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood cell counts before you start Jakafi and regularly during your treatment with Jakafi. Tell your healthcare provider right away if you develop or have worsening of any of these symptoms:</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>unusual bleeding</item>
                                 <item>bruising</item>
                                 <item>tiredness</item>
                              </list>
                           </td>
                           <td styleCode=" Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>shortness of breath</item>
                                 <item>fever</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Infection.</content> You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection:</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>chills</item>
                                 <item>aches</item>
                                 <item>fever</item>
                                 <item>nausea</item>
                              </list>
                           </td>
                           <td styleCode=" Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>vomiting</item>
                                 <item>weakness</item>
                                 <item>painful skin rash or blisters</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Cancer.</content> Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi<content styleCode="bold">.</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold"> </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Cholesterol increases.</content> You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.</paragraph>
                              <paragraph>
                                 <content styleCode="bold"> </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis.</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold"> </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">  </content>Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including:</paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back</item>
                                 <item>severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw</item>
                                 <item>pain or discomfort in your arms, back, neck, jaw, or stomach</item>
                                 <item>shortness of breath with or without chest discomfort</item>
                                 <item>breaking out in a cold sweat</item>
                                 <item>nausea or vomiting</item>
                                 <item>feeling lightheaded</item>
                                 <item>weakness in one part or on one side of your body</item>
                                 <item>slurred speech</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Increased risk of blood clots. </content>Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening.<br/>
                                 <br/>
                              </paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including:<br/> º  swelling, pain or tenderness in one or both legs<br/> º  sudden, unexplained chest or upper back pain<br/> º  shortness of breath or difficulty breathing</item>
                              </list>
                              <paragraph>
                                 <br/>
                                 <content styleCode="bold">Possible increased risk of new (secondary) cancers.</content> People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.<br/>
                              </paragraph>
                              <br/>
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of Jakafi in adults with certain types of MF and PV include:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>low platelet counts</item>
                                 <item>low red blood cell counts</item>
                                 <item>bruising</item>
                              </list>
                           </td>
                           <td styleCode=" Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>dizziness</item>
                                 <item>headache</item>
                                 <item>diarrhea</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of Jakafi in people with aGVHD include:<br/>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>low red blood cell counts</item>
                                 <item>low platelet counts</item>
                                 <item>low white blood cell counts</item>
                              </list>
                           </td>
                           <td styleCode=" Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>infections</item>
                                 <item>swelling</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule"> <br/>
                              <content styleCode="bold">The most common side effects of Jakafi in people with cGVHD include:<br/>
                              </content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>low red blood cell counts</item>
                                 <item>low platelet counts </item>
                              </list>
                           </td>
                           <td styleCode=" Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item> infections, including viral infections</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Lrule Rrule">These are not all of the possible side effects of Jakafi. <br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. <br/>You may also report side effects to Incyte Corporation at 1-855-463-3463.</td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I store Jakafi?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>Store Jakafi at room temperature 68°F to 77°F (20°C to 25°C).</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep Jakafi and all medicines out of the reach of children.<br/>    </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of Jakafi.<br/>
                                 <br/>
                              </content>Medicines are sometimes prescribed for purposes other than those listed in Patient Information. Do not use Jakafi for a condition for which it is not prescribed. Do not give Jakafi to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information that is written for healthcare professionals.<br/>   </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in Jakafi?<br/>
                                 </content>
                                 <content styleCode="bold">
                                    <br/>Active ingredient</content>: ruxolitinib phosphate<br/>
                                 <br/>
                                 <content styleCode="bold">Inactive ingredients</content>: microcrystalline cellulose, lactose monohydrate, magnesium stearate, colloidal silicon dioxide, sodium starch glycolate, povidone and hydroxypropyl cellulose<br/>
                                 <br/>Manufactured for: Incyte Corporation, 1801 Augustine Cut-off, Wilmington, DE 19803<br/>
                                 <br/>Jakafi is a registered trademark of Incyte. All rights reserved.<br/>U.S. Patent Nos. 7598257; 8415362; 8722693; 8822481; 8829013; 9079912; 9814722; 10016429<br/>
                                 <br/>© 2011-2021 Incyte Corporation. All rights reserved.<br/>For more information call 1-855-463-3463 or go to <linkHtml href="http://www.jakafi.com">www.jakafi.com</linkHtml>.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration.				Revised: September 2021<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20250624"/>
            </section>
         </component>
         <component>
            <section ID="LINK_9a1db97b-cddf-4aab-b814-f77acce19de8">
               <id root="17c6ca33-bb5f-4a94-b1ac-ef56a4f6bf8b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>5 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>Rx only</paragraph>
                  <paragraph>NDC 50881-005-60</paragraph>
                  <paragraph>Jakafi® (Ruxolitinib) Tablets</paragraph>
                  <paragraph>5 mg</paragraph>
                  <paragraph>60 tablets</paragraph>
                  <paragraph>Each tablet contains 6.6 mg ruxolitinib phosphate equivalent to 5 mg ruxolitinib free base.</paragraph>
                  <renderMultiMedia referencedObject="MM7"/>
               </text>
               <effectiveTime value="20250624"/>
               <component>
                  <observationMedia ID="MM7">
                     <text>Jakafi (Ruxolitinib) 5mg Tablets - 60 Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="jakafi-7.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5ece5bc3-b201-4b61-8068-2849e56b4c38">
               <id root="a40846b5-09a4-47f3-9d5f-441d7c13388d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>10 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>Rx only</paragraph>
                  <paragraph>NDC 50881-010-60</paragraph>
                  <paragraph>Jakafi® (Ruxolitinib) Tablets</paragraph>
                  <paragraph>10 mg</paragraph>
                  <paragraph>60 tablets</paragraph>
                  <paragraph>Each tablet contains 13.2 mg ruxolitinib phosphate equivalent to 10 mg ruxolitinib free base.</paragraph>
                  <renderMultiMedia referencedObject="MM8"/>
               </text>
               <effectiveTime value="20250624"/>
               <component>
                  <observationMedia ID="MM8">
                     <text>Jakafi (Ruxolitinib) 10mg Tablets - 60 Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="jakafi-8.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_4acee47f-5e59-468a-a527-7b6d472cf431">
               <id root="d5776255-6ef0-4911-8e6b-78f0afcf5191"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>15 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>Rx only</paragraph>
                  <paragraph>NDC 50881-015-60</paragraph>
                  <paragraph>Jakafi® (Ruxolitinib) Tablets</paragraph>
                  <paragraph>15 mg</paragraph>
                  <paragraph>60 tablets</paragraph>
                  <paragraph>Each tablet contains 19.8 mg ruxolitinib phosphate equivalent to 15 mg ruxolitinib free base.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM9"/>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20250624"/>
               <component>
                  <observationMedia ID="MM9">
                     <text>Jakafi (Ruxolitinib) 15mg Tablets - 60 Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="jakafi-9.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_d50b6732-9f52-494a-8179-972ec80d6b12">
               <id root="5627210e-20a7-42e0-92cc-1c371d03e452"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>20 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>Rx only</paragraph>
                  <paragraph>NDC 50881-020-60</paragraph>
                  <paragraph>Jakafi® (Ruxolitinib) Tablets</paragraph>
                  <paragraph>20 mg</paragraph>
                  <paragraph>60 tablets</paragraph>
                  <paragraph>Each tablet contains 26.4 mg ruxolitinib phosphate equivalent to 20 mg ruxolitinib free base.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM10"/>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20250624"/>
               <component>
                  <observationMedia ID="MM10">
                     <text>Jakafi (Ruxolitinib) 20mg Tablets - 60 Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="jakafi-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_b835d1ec-9696-4987-9fed-625d1cd50e9e">
               <id root="7b79ccf5-cd5d-4831-8d80-c0c10f8f6de4"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>25 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>Rx only</paragraph>
                  <paragraph>NDC 50881-025-60</paragraph>
                  <paragraph>Jakafi® (Ruxolitinib) Tablets</paragraph>
                  <paragraph>25 mg</paragraph>
                  <paragraph>60 tablets</paragraph>
                  <paragraph>Each tablet contains 33 mg ruxolitinib phosphate equivalent to 25 mg ruxolitinib free base.</paragraph>
                  <renderMultiMedia referencedObject="MM11"/>
               </text>
               <effectiveTime value="20250624"/>
               <component>
                  <observationMedia ID="MM11">
                     <text>Jakafi (Ruxolitinib) 25mg Tablets - 60 Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="jakafi-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>